Propanc Biopharma (PPCBD) S-1/A 6 Oct 23 IPO registration (amended) Financial data

Cover

Cover	12 Months Ended
	Jun. 30, 2023
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	AMENDMENT NO. 1
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Primary SIC Number	2834
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell, VIC
Entity Address, Postal Zip Code	3124
City Area Code	61 03
Local Phone Number	9882 6723
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell, VIC
Entity Address, Postal Zip Code	3124
City Area Code	61 03
Local Phone Number	9882 6723
Contact Personnel Name	James Nathanielsz

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Jun. 30, 2022
CURRENT ASSETS:
Cash	$ 10,047	$ 4,067
GST tax receivable	2,867	2,342
Prepaid expenses and other current assets	6,125	8,621
TOTAL CURRENT ASSETS	19,039	15,030
Property and equipment, net	302	2,023
TOTAL ASSETS	60,328	81,651
CURRENT LIABILITIES:
Accounts payable	966,718	943,023
Accrued expenses and other payables	579,707	466,115
Accrued interest	44,709	57,822
Loan from former director - related party	65,280
Convertible notes, net of discounts and including put premiums	390,539	926,438
Embedded conversion option liabilities	423,209	151,262
Employee benefit liability	587,618	415,799
TOTAL CURRENT LIABILITIES	3,158,229	3,062,981
NON-CURRENT LIABILITIES:
TOTAL NON-CURRENT LIABILITIES	19,278	42,319
TOTAL LIABILITIES	3,177,507	3,105,300
Commitments and Contingencies (See Note 9)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 6,031,250 and 220,351 shares issued and outstanding as of June 30, 2023 and 2022, respectively	6,031	220
Common stock issuable (1,621,653 and 19,597 shares as of June 30, 2023 and 2022, respectively)	1,621	20
Additional paid-in capital	60,311,502	57,364,690
Subscription receivable		(23,758)
Accumulated other comprehensive income	1,294,876	1,234,549
Accumulated deficit	(64,684,732)	(61,557,893)
Treasury stock (0.001 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(3,117,179)	(3,023,649)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	60,328	81,651
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, value		5,000
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock, value
Related Party [Member]
CURRENT ASSETS:
Security deposit - related party	1,999	2,075
Operating lease right-of-use assets, net - related party	38,988	62,523
CURRENT LIABILITIES:
Loan from former director - related party	49,314	51,171
Operating lease liability - related party, current portion	21,505	20,605
Due to former director - related party	29,630	30,746
NON-CURRENT LIABILITIES:
Operating lease liability - long-term portion - related party	$ 19,278	$ 42,319

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Jun. 30, 2022
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	6,031,250	220,351
Common stock, shares outstanding	6,031,250	220,351
Common stock, shares issuable	1,621,653	19,597
Treasury stock, shares	0.001	0.001
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	0	500,000
Preferred stock, shares outstanding	0	500,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	1,499,885	1,706,452
Occupancy expenses - related party	28,841	28,366
Research and development	247,919	256,052
TOTAL OPERATING EXPENSES	1,776,645	1,990,870
LOSS FROM OPERATIONS	(1,776,645)	(1,990,870)
OTHER INCOME (EXPENSE)
Interest expense	(532,821)	(568,798)
Interest income	36	5,613
Change in fair value of derivative liabilities	(530,330)	(99,111)
Gain from settlement of accounts payable	17,499
Gain (loss) on extinguishment of debt, net	25,969	(17,503)
Foreign currency transaction gain (loss)	5,885	(42,395)
TOTAL OTHER EXPENSE, NET	(1,013,762)	(722,194)
LOSS BEFORE TAXES	(2,790,407)	(2,713,064)
Tax benefit	129,841	54,977
NET LOSS	(2,660,566)	(2,658,087)
Deemed Dividend	(466,273)	(700,340)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (3,126,839)	$ (3,358,427)
Net loss per share available to common stockholders - basic	$ (1.80)	$ (49.23)
Net loss per share available to common stockholders - diluted	$ (1.80)	$ (49.23)
Weighted Average shares outstanding - basic	1,738,802	68,219
Weighted Average shares outstanding - diluted	1,738,802	68,219
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (3,126,839)	$ (3,358,427)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	60,327	149,345
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	60,327	149,345
TOTAL COMPREHENSIVE LOSS	$ (3,066,512)	$ (3,209,082)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock, Common [Member]	Total
Balance at Jun. 30, 2021	$ 5,000		$ 14		$ 54,088,152		$ (58,199,466)	$ 1,085,204	$ (46,477)	$ (3,067,573)
Balance, shares at Jun. 30, 2021	500,000	1	14,055	1
Issuance of common stock for cash			$ 26		123,017	(23,758)				99,285
Issuance of common stock for cash, shares			25,663
Issuance of common stock for offering cost			$ 1		(1)
Issuance of common stock for offering cost, shares			1,000
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 97	$ 7	657,021					657,125
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			96,960	7,326
Issuance of common stock for services and accrued expenses			$ 26	$ 12	763,027					763,065
Issuance of common stock for services and accrued expenses, shares			25,857	12,271
Issuance of common stock for exercise of Series B warrants					625,001					625,001
Issuance of common stock for exercise of warrants, shares			16
Issuance of common stock for alternate cashless exercise of Series A warrants			$ 57		(57)
Issuance of common stock for alternate cashless exercise of warrants, shares			56,800
Reclassification of put premium upon debt conversion					335,677					335,677
Stock based compensation in connection with stock option grants					72,513					72,513
Foreign currency translation gain								149,345		149,345
Deemed dividend upon alternate cashless exercise of warrants					700,340		(700,340)
Net loss							(2,658,087)			(2,658,087)
Balance at Jun. 30, 2022	$ 5,000		$ 220	$ 20	57,364,690	(23,758)	(61,557,893)	1,234,549	(46,477)	(3,023,649)
Balance, shares at Jun. 30, 2022	500,000	1	220,351	19,598
Issuance of common stock for cash			$ 14		24,697	23,758				48,469
Issuance of common stock for cash, shares			14,337
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 5,061	$ 807	1,381,855					1,387,723
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			5,061,180	807,230
Issuance of common stock for exercise of Series B warrants					475,000					475,000
Issuance of common stock for exercise of warrants, shares			12	0
Issuance of common stock for alternate cashless exercise of Series A warrants			$ 560	$ 206	(766)
Issuance of common stock for alternate cashless exercise of warrants, shares			559,999	206,000
Reclassification of put premium upon debt conversion					411,111					411,111
Foreign currency translation gain								60,327		60,327
Deemed dividend upon alternate cashless exercise of warrants					466,273		(466,273)
Net loss							(2,660,566)			(2,660,566)
Retirement of Series A Preferred Stock	(5,000)				5,000
Retirement of Series A Preferred Stock, shares	(500,000)
Issuance of common stock for services			$ 79	$ 608	138,261					138,948
Issuance of common stock for services, shares			79,412	608,423
Issuance of common stock in connection with a note payable			$ 75		37,425					37,500
Issuance of common stock in connection with a note payable, shares			75,000
Issuance of common stock for issuable shares			$ 20	$ (20)
Issuance of common stock for issuable shares, shares			19,598	(19,598)
Warrant grant for settlement of accounts payable					5,551					5,551
Stock based compensation in connection with stock warrant grant					2,408					2,408
Fractional shares due to reverse split			$ 2		(2)
Fractional difference due to the reverse stock-split, shares			1,361
Balance at Jun. 30, 2023			$ 6,031	$ 1,621	$ 60,311,502		$ (64,684,732)	$ 1,294,876	$ (46,477)	$ (3,117,179)
Balance, shares at Jun. 30, 2023		1	6,031,250	1,621,653

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,660,566)	$ (2,658,087)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance and amortization of common stock for services	138,948	314,626
Stock option, stock warrants and restricted stock expense	2,408	72,513
Foreign currency transaction (gain) loss	(5,885)	42,395
Depreciation expense	1,665	1,993
Amortization of debt discounts	202,952	47,971
Amortization of right-of-use assets	21,266	3,678
Change in fair value of derivative liabilities	530,330	99,111
(Gain) loss on extinguishment of debt, net	(25,969)	17,503
Gain from settlement of accounts payable	(17,499)
Non-cash interest expense	1,838	2,250
Accretion of put premium	232,674	452,308
Changes in Assets and Liabilities:
GST receivable	(610)	1,660
Prepaid expenses and other assets	2,182	(8,620)
Accounts payable	80,975	18,870
Employee benefit liability	186,912	29,907
Accrued expenses and other payables	130,511	65,017
Accrued interest	92,474	63,878
Operating lease liability	(19,857)	(3,277)
NET CASH USED IN OPERATING ACTIVITIES	(1,105,251)	(1,436,304)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	590,250	766,500
Proceeds from the sale of common stock	24,711	99,285
Collection of subscription receivable	23,758
Proceeds from the exercise of warrants	475,000	625,001
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,113,719	1,490,786
Effect of exchange rate changes on cash	(2,488)	(52,670)
NET INCREASE IN CASH	5,980	1,812
CASH AT BEGINNING OF YEAR	4,067	2,255
CASH AT END OF YEAR	10,047	4,067
Supplemental Disclosure of Cash Flow Information
Interest	2,883	2,392
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Common stock issued for offering cost applied against proceeds received		20,000
Subscription receivable		23,758
Reduction of put premium related to conversions of convertible notes	411,111	335,677
Conversion of convertible notes and accrued interest to common stock	1,016,285	635,303
Debt discounts related to derivative liability	93,668
Operating lease right-of-use asset and operating lease liability pursuant to ASC 842		66,201
Debt discounts related to common stock issued with a note payable	37,500
Warrant grant for settlement of accounts payable	5,551
Common stock issued for accrued services		448,440
Deemed dividend upon alternate cashless exercise of warrants	$ 466,273	$ 700,340

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2023, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 62 granted, allowed, or accepted patents and 14 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through June 30, 2023. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of June 30, 2023 and 2022, the Company recognized a cumulative exchange gain (loss) of approximately $ 648,000 1,289,000 As of June 30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES June 30, 2023 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6664 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6732 0.7253 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2023 and 2022 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Beginning balance, June 30, 2021 $ 1,085,204 Foreign currency translation gain 149,345 Balance, June 30, 2022 1,234,549 Foreign currency translation gain 60,327 Ending balance, June 30, 2023 $ 1,294,876 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts, as applicable, are reflected as a current liability on the balance sheets. There were no Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through June 30, 2023 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2023 and 2022, the Company was owed $ 2,867 2,342 Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 247,919 256,052 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. During each of the fiscal years ended June 30, 2023 and 2022, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 129,841 54,977 Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Legal Expenses All legal costs for litigation are charged to expense as incurred. Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations and relate to the presentation of accrued interest separately on the consolidated balance sheet, of which $ 57,822 Basic and Diluted Net Loss Per Common Share Basic net loss per share of common stock is computed by dividing the net loss by the weighted average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants, restricted stock units and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per-share amounts for all periods presented are identical. Each holder of the notes and warrants has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS June 30, 2023 June 30, 2022 Stock Options 0.06 0.06 Warrants with no designations 90 105 Series A Warrants as if converted at alternate cashless exercise prices 1,996,625,990 - Series B Warrants 16 - Series C Warrants as if converted at alternate cashless exercise prices * 9,473,999,953 - Unvested restricted stock units 0.06 0.06 Convertible Debt 5,991,195 127,062 Total 11,476,617,244.12 127,167.12 * Only convertible ratably upon exercise of Series B Warrants PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term with the exception of those disclosed below. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on its consolidated financial statements.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the fiscal year ended June 30, 2023, the Company had no revenues, had a net loss of $ 2,660,566 1,105,251 3,139,190 3,117,179 64,684,732 The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute its business plan. However, there can be no assurances that any or all of these endeavors will be successful. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following as of June 30: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2023 2022 Office equipment at cost $ 25,432 $ 28,623 Less: Accumulated depreciation (25,130 ) (26,600 ) Total property, plant, and equipment $ 302 $ 2,023 Depreciation expense for the years ended June 30, 2023 and 2022 were $ 1,665 1,993

DUE TO FORMER DIRECTOR - RELATE

DUE TO FORMER DIRECTOR - RELATED PARTY	12 Months Ended
	Jun. 30, 2023
Due To Former Director - Related Party
DUE TO FORMER DIRECTOR - RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to former director – related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amounts owed to the former director at June 30, 2023 and 2022 were $ 29,630 30,746

LOANS

LOANS	12 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
LOANS	NOTE 5 – LOANS Loan from Former Director - Related Party Loan from the Company’s former director at June 30, 2023 and 2022 was $ 49,314 51,171 Loan Payable Crown Bridge Securities Purchase Agreement Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, LLC (“Crown Bridge”), pursuant to which Crown Bridge purchased a convertible promissory note from the Company (the “Crown Bridge Note”), which had a remaining principal balance of $ 65,280 October 3, 2020 15 65,280 43,520 35,722 Loan in default The Crown Bridge Note is currently past due and in default, consisting of $ 65,280 35,722 15 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Jun. 30, 2023
Convertible Notes
CONVERTIBLE NOTES	NOTE 6 – CONVERTIBLE NOTES The Company’s convertible notes outstanding at June 30, 2023 and 2022 were as follows: SCHEDULE OF CONVERTIBLE NOTES June 30, 2023 June 30, 2022 Convertible notes and debenture $ 338,362 $ 644,980 Unamortized discounts (38,994 ) (31,669 ) Premium, net 91,171 313,127 Convertible notes, net $ 390,539 $ 926,438 Convertible Note Issued with Consulting Agreement August 10, 2017 Consulting Agreement On August 10, 2017, the Company entered into a consulting agreement, retroactive to May 16, 2017, with a certain consultant, pursuant to which the consultant agreed to provide certain consulting and business advisory services in exchange for a $ 310,000 10% 750 65% August 10, 2019 155,000 155,000 18% 578,212 140,000 10,764 161,000 19,418 9,000 500 5,248 8,500 22,168 On March 15, 2021, the Company entered into a Settlement and Mutual Release Agreement (the “Settlement Agreement”) with the consultant whereby both parties agreed to settle all claims and liabilities under the August 10, 2017 Convertible note for a total of $ 100,000 56,762 8,500 23,262 25,000 43,238 The total principal and accrued interest outstanding under the August 10, 2017 convertible note was $ 79,000 10,185 1,000 8,000 The total principal and accrued interest outstanding under the August 10, 2017 Convertible Note was $ 0 79,000 9,543 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Auctus Fund Financing Agreements August 30, 2019 Securities Purchase Agreement Effective August 30, 2019, the Company entered into a securities purchase agreement with Auctus Fund, LLC (“Auctus”), pursuant to which Auctus purchased a convertible promissory note (the “August 30, 2019 Auctus Note”) from the Company in the aggregate principal amount of $ 550,000 550,000 5,000 40,000 505,000 August 30, 2020 10% 366,667 24% Additionally, Auctus had the option to convert all or any amount of the principal face amount and accrued interest of the August 30, 2019 Auctus Note, at any time following the issue date and ending on the later of the maturity date or the date of payment of the Default Amount if an event of default occurs, which was an amount equal to 125% 15,000 24% Upon the holder’s election to convert accrued interest, default interest or any penalty amounts as stipulated, the Company may elect to pay those amounts in cash. The note may also be prepaid by the Company at any time between the date of issuance and August 13, 2020 at 135% multiplied by the sum of (a) the then outstanding principal amount plus (b) accrued and unpaid interest plus (c) default interests, if any. The conversion price for the August 30, 2019 Auctus Note was a Variable Conversion Price, being 60% 4.99% In connection with the issuance of the August 2019 Auctus Note, the Company issued common stock purchase warrants to Auctus to purchase 450 shares of the Company’s common stock (the “First Warrant”) as a commitment fee upon the terms and subject to the limitations and conditions set forth in such First Warrant at an “Exercise Price” of $ 2,250,000 300 3,330,000 225 4,500,000 4.99% 375,905 In connection with the Purchase Agreement, the Company and the Purchaser entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to register the shares of Common Stock underlying the Securities in a Registration Statement with the SEC as well as the Commitment Shares (as defined herein). The Registration Rights Agreement contains customary representations, warranties, agreements and indemnification rights and obligations of the parties. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The Note was subject to customary default provisions and also includes a cross-default provision which provides that a breach or default by the Borrower of any covenant or other term or condition contained in any of the Other Agreements (as defined therein), after the passage of all applicable notice and cure or grace periods, shall, at the option of the Holder, be considered a default under this Note and the Other Agreements. Upon occurrence of any such event, the Holder was entitled (but in no event required) to apply all rights and remedies of the Holder under the terms of this Note and the Other Agreements by reason of a default under said Other Agreements or the Note. The August 30, 2019 Auctus Note contained certain events of default, upon which principal and accrued interest were to become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% The total principal amount outstanding under the above Auctus financing agreement, specifically the August 30, 2019 Auctus Note, was $ 358,965 486 191,035 43,176 127,356 The total principal amount outstanding under the above Auctus financing agreement, specifically the August 30, 2019 Auctus Note, was $ 32,848 0 326,117 39,536 217,411 The total principal amount outstanding under the above Auctus financing agreement, specifically the August 30, 2019 Auctus Note, was $ 0 0 32,848 716 21,899 no Crown Bridge Securities Purchase Agreements Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge, pursuant to which Crown Bridge purchased the Crown Bridge Note from the Company in the aggregate principal amount of $ 108,000 3,000 5,000 100,000 15% Additionally, Crown Bridge had the option to convert all or any amount of the Crown Bridge Note at any time after issuance until the later of such note’s maturity date or the date on which the default amount was paid if an event of default occurs, which would be between 110% 150% The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received. 4.99% 9.99% 72,000 The Crown Bridge Note contained certain events of default, upon which principal and accrued interest would become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal accrued at a default interest rate of 15% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The total principal amount outstanding under the Crown Bridge Note was $ 65,280 7,232 42,720 28,480 There were 15 st 9,600 6,400 16,000 The total principal amount outstanding under the Crown Bridge Note was $ 65,280 25,930 In August 2022, the SEC filed a complaint against Crown Bridge due to its violation of Section 15(a)(1) of the Exchange Act. Crown Bridge agreed to surrender all conversion rights in its currently held convertible notes, including the Crown Bridge Note. Consequently, as of June 30, 2023, the Company reclassified the remaining principal balance of $ 65,280 43,520 0 GW Holdings Securities Purchase Agreements October 1, 2019 Securities Purchase Agreement Effective October 1, 2019, the Company entered into a securities purchase agreement with GW Holdings, pursuant to which GW Holdings purchased a convertible promissory note (the “October 1, 2019 GW Note”) from the Company in the aggregate principal amount of $ 131,000 6,000 125,000 October 1, 2020 8% December 10, 2020 Securities Purchase Agreement Effective December 10, 2020, the Company entered into a securities purchase agreement with GW Holdings, pursuant to which GW Holdings purchased a convertible promissory note (the “December 10, 2020 GW Note”) from the Company in the aggregate principal amount of $ 131,000 6,000 125,000 December 10, 2021 8% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The above notes issued to GW Holdings contain certain events of default, upon which principal and accrued interest were to become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% Additionally, GW Holdings had the option to convert all or any amount of the principal face amount of the notes issued to GW Holdings at any time from the date of issuance and ending on the later of the maturity date or the date the Default Amount is paid if an event of default occurs, which is an amount between 110% 150% The conversion price for the above GW Holdings notes was equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion was received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99% 9.99% These notes were treated as stock settled debt under ASC 480 and accordingly the Company recorded a total of $ 174,666 The total principal amount outstanding under the above October 1, 2019 GW Holdings financing agreement was $ 30,000 1,776 101,000 5,082 0 30,000 3,877 67,333 20,000 The total principal amount outstanding under the above December 10, 2020 GW Holdings financing agreement, was $ 90,000 4,636 41,000 1,084 27,333 The total principal amount outstanding and accrued interest under the above December 10, 2020 GW Holdings financing agreement, was $ 0 90,000 7,885 4,000 60,000 Geneva Roth Remark Securities Purchase Agreements December 2, 2020 Securities Purchase Agreement Effective December 2, 2020, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc.(“Geneva Roth”), pursuant to which Geneva Roth purchased a convertible promissory note (the “December 2, 2020 Geneva Roth”) from the Company in the aggregate principal amount of $ 78,000 3,000 December 2, 2021 8% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 January 5, 2021 Securities Purchase Agreement Effective January 5, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “January 5, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 68,500 3,500 January 5, 2022 8% March 16, 2021 Securities Purchase Agreement Effective March 16, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “March 16, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 63,500 3,500 The maturity date of the March 16, 2021 Geneva Roth Note was March 16, 2022 8% August 19, 2021 Securities Purchase Agreement Effective August 19, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “August 19, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 103,750 3,750 August 19, 2022 8% September 22, 2021 Securities Purchase Agreement Additionally, effective September 22, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “September 22, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 63,750 3,750 September 22, 2022 8% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 During the first 60 to 180 days following the date of these notes, the Company had the right to prepay the principal and accrued but unpaid interest due under the above notes issued to Geneva Roth, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110% 129% The conversion price for the above Geneva Roth notes was equal to a 35% 9.99% 203,269 The above Geneva Roth notes contained certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22% The total principal amounts outstanding under the above Geneva Roth financing agreements were $ 132,000 3,477 78,000 3,120 42,000 The total principal amounts outstanding under the above Geneva Roth financing agreements were $ 0 299,500 11,980 161,269 1800 Diagonal Lending (formerly known as Sixth Street Lending) Securities Purchase Agreements October 21, 2021 Securities Purchase Agreement Effective October 21, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC (“Sixth Street”), pursuant to which Sixth Street purchased a convertible promissory note (the “October 21, 2021 Sixth Street Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 October 21, 2022 8% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 November 26, 2021 Securities Purchase Agreement Effective November 26, 2021, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “November 26, 2021 Sixth Street Note”) from the Company in the aggregate principal amount of $ 53,750 3,750 November 26, 2022 8% January 4, 2022 Securities Purchase Agreement Effective January 4, 2022, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “January 4, 2022 Sixth Street Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 January 4, 2023 8% March 7, 2022 Securities Purchase Agreement Effective March 7, 2022, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “March 7, 2022 Sixth Street Note”) from the Company in the aggregate principal amount of $ 68,750 3,750 March 7, 2023 8% April 12, 2022 Securities Purchase Agreement Effective April 12, 2022, the Company entered into a securities purchase agreement with Sixth Street, pursuant to which Sixth Street purchased a convertible promissory note (the “April 12, 2022 Sixth Street Note”) from the Company in the aggregate principal amount of $ 68,750 3,750 April 12, 2023 8% May 12, 2022 Securities Purchase Agreement Effective May 12, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), pursuant to which 1800 Diagonal purchased a convertible promissory note (the “May 12, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 May 12, 2023 8% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 June 30, 2022 Securities Purchase Agreement On June 30, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal, which closed on July 11, 2022, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 11, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 105,000 3,750 June 30, 2023 8% The following terms apply to all of the above 1800 Diagonal notes: During the first 60 to 180 days following the date of the above listed notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110% 129% The conversion price for the above 1800 Diagonal notes is equal to 65% 9.99% 262,500 56,538 The above 1800 Diagonal notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal accrues at a default interest rate of 22% Such events of default include, among others, failure to timely issue shares upon receipt of a notice of conversion, breach of covenants, representations or warranties, insolvency, bankruptcy and liquidation (subject to cure periods), failure by the Company to pay the principal and interest due under such note, failure to reserve at least five times the number of shares issuable upon full conversion of such note, failure to maintain the listing of the common stock on at least one of the OTC markets or a national exchange, restatement of the Company’s financial statements at any time after 180 days after the issuance date of such note if such restatement would reasonably constitute a material adverse effect on 1800 Diagonal, the Company’s failure to comply with Exchange Act reporting requirements or the Company ceases to be subject to such reporting requirements. Failure to deliver shares of common stock upon conversion of the above 1800 Diagonal notes within three business days of a notice of conversion will result in the Company paying a penalty of $ 1,000 Upon certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company must pay 1800 Diagonal 150% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The total principal amount outstanding under the above 1800 Diagonal notes was $ 265,000 6,081 117,500 4,700 63,269 The total principal amount outstanding and accrued interest under the above 1800 Diagonal notes was $ 0 370,000 14,800 199,230 ONE44 Capital Securities Purchase Agreements December 7, 2021 Securities Purchase Agreement Effective December 7, 2021, the Company entered into a securities purchase agreement with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “December 7, 2021 ONE44 Note”) from the Company in the aggregate principal amount of $ 170,000 25,500 December 7, 2022 10% March 29, 2022 Securities Purchase Agreement Effective March 29, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible promissory note (the “March 29, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 120,000 18,000 March 29, 2023 10% August 15, 2022 Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 10,000 5,500 August 15, 2023 10% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 February 14, 2023 Securities Purchase Agreement On February 14, 2023, the Company entered into a securities purchase agreement with ONE44, pursuant to which ONE44 purchased a convertible redeemable note (the “February 14, 2023 ONE44 Note”) from the Company in the aggregate principal amount of $ 111,111 11,111 5,500 February 14, 2024 10% The following terms apply to all of the above ONE44 notes: During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe ONE44 under the terms of the note, at a premium ranging from 120% 135% The conversion price for the above ONE44 notes ranges from 60% 65% 289,459 133,305 The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24% 250 th 500 th 20% The total principal amount outstanding under the above ONE44 notes was $ 235,700 9,519 54,300 2,873 29,238 The total principal amount outstanding under the above ONE44 notes was $ 118,111 4,726 338,700 24,255 182,376 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 GS Capital Partners Securities Purchase Agreements August 12, 2022 Securities Purchase Agreement On August 12, 2022, the Company entered into a securities purchase agreement (the “GS Capital Purchase Agreement”) with GS Capital Partners, LLC (“GS Capital”), pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 93,000 5,000 3,000 85,000 The maturity date of the GS Capital Note was April 12, 2023, but was extended to August 12, 2023 8% The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price becomes $1.30 per share. 65% 4.99% Additionally, such conversion price will be adjusted if the Company issues securities with more favorable conversion terms. Currently, the effective conversion price of this note is 60% September 21, 2022 Securities Purchase Agreement On September 21, 2022, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 71,500 4,000 2,500 65,000 The maturity date of such note is March 21, 2023 but was extended to March 21, 2024 8% Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share. 65% 4.99% Additionally, the conversion price will be adjusted in favor of the note holder if the Company issues securities with more favorable conversion terms. Currently, the effective conversion price of this note is 60% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe GS Capital under the terms of the notes, at a premium ranging from 110% 125% Upon the occurrence and during the continuation of certain events of default, interest accrues at a default interest rate of 24% 250 th 500 th 20% The total principal outstanding and accrued interest under the above GS Capital notes were $ 75,300 4,263 89,200 2,945 75,300 Red Road Holdings Securities Purchase Agreement On October 6, 2022, the Company entered into a securities purchase agreement (the “Red Road Purchase Agreement”) with Red Road Holdings Corporation, a Virginia corporation (“Red Road”), pursuant to which Red Road purchased a convertible promissory note (the “Red Road Note”) from the Company in the aggregate principal amount of $ 53,750 50,000 8% 22% 3,750 The conversion price for the Red Road Note was equal to the Variable Conversion Price (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events), which was defined as 65% 4.99% 28,942 The Red Road Note may be prepaid until 180 days from its issuance date, subject to the following: if prepaid within 60 days of the issuance date, the prepayment premium is 110% of the face amount of such note plus any accrued interest, if prepaid after 60 days but less than 91 days from the issuance date, then the prepayment premium is 115% of the face amount plus any accrued interest of such note., if prepaid after 90 days but less than 121 days from the issuance date, then the prepayment premium is 120% of the face amount plus any accrued interest of such note, if prepaid after 120 days but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest of such note, and if prepaid after 150 days but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest of such note. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 In the event that the Company failed to deliver to Red Road shares of common stock upon conversion of the Red Road Note within three business days of a notice of conversion by Red Road, the Company would incur a penalty of $ 1,000 The total principal amount outstanding and accrued interest under the above Red Road notes was $ 0 53,750 2,150 28,942 Coventry Enterprises, LLC Securities Purchase Agreement On November 3, 2022, the Company entered into a Securities Purchase Agreement with Coventry Enterprises, LLC (“Coventry”), pursuant to which the Company issued Coventry a promissory note from the Company in the aggregate principal amount of $ 125,000 25,000 100,000 The Coventry Note bears interest at a rate of 10% 12,500 19,643 Additionally, in the event that the Company files with the SEC a qualified offering statement on Form 1-A and such note has been outstanding for four months since its issuance, Coventry has the right to convert all or portion of such note, including guaranteed interest, into shares of common stock at the offering price used in connection with such offering. At any time following an event of default under the Coventry Note, it becomes convertible, in whole or in part, into shares of Common Stock at the option of Coventry, at any time and from time to time thereafter (subject to the beneficial ownership limitations set forth therein). The conversion price of the Coventry Note is ninety percent (90%) per share of the lowest per-share VWAP during the twenty (20) trading-day period before the conversion (each, a “Calculated Conversion Price”). In the event that, within 30 calendar days either before or after any conversion, the conversion price of which is based upon a Calculated Conversion Price, the Company consummates (in whole or in part) any financing (whether such financing is equity, equity-equivalent, or debt or any combination thereof) or for any other reason issues any shares of common stock or any common stock equivalents at a price less than the most recent Calculated Conversion Price (the “Alternative Conversion Price”), regardless of when that note or instrument was originated, then, at the option of Coventry, (i) if the conversion has not yet occurred, then the Alternative Conversion Price will be substituted for the Calculated Conversion Price and (ii) if the conversion has occurred, then, within two trading days following Coventry’s written request, the Company is required to issue to Coventry that number of shares of Common Stock equivalent to the difference between the number of shares of Common Stock that had been issued using the Calculated Conversion Price and the number of shares of Common Stock that would have been issued using the Alternative Conversion Price. Accordingly, the Coventry note is treated as stock settled debt under ASC 480 and the Company recorded a total of $ 13,889 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Upon the occurrence and during the continuation of certain events of default, interest on the Coventry Note accrues at a default interest rate equal to the lesser of (i) 18% per annum or (ii) the maximum rate permitted by law. Subject to the beneficial ownership limitation in the Coventry Note, if any event of default occurs, then the outstanding principal amount guaranteed interest plus accrued but unpaid default rate interest, liquidated damages and other amounts owing on the Coventry Note through the date of acceleration becomes immediately due and payable at Coventry’s option, in cash or in shares of common stock at the mandatory default amount, which is equal to 120% of all such amounts due on the Coventry Note. If the Company fails to deliver to Coventry such shares, the Company is required to pay in cash an amount equal to the amount that the value of such shares exceeds the principal amount and interest of the attempted conversion. As an additional inducement to Coventry entering into such agreement, the Company issued to Coventry 75,000 37,500 The Company failed to make the first installment payment due in March 2023 which is considered an event of default. The Company recorded a default penalty of $ 25,000 The total principal amount outstanding and accrued interest under the above Coventry note was $ 144,951 5,049 22,749 561 142,908 Convertible note in default The Coventry Note is currently past due and in default, consisting of $ 144,951 22,749 18 Amortization of debt discounts The Company recorded $ 210,278 73,500 232,674 452,308 Amortization of all debt discounts for the years ended June 30, 2023 and 2022 was $ 202,952 47,971 The Company reclassified $ 411,111 335,677

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7 – INCOME TAXES The Company follows ASC 740-10-10, under which an entity recognizes deferred tax assets and liabilities for future tax consequences or for events that were previously recognized in the Company’s financial statements or tax returns. The measurement of deferred tax assets and liabilities is based on enacted tax law provisions. The effects of future changes in tax laws or rates are not anticipated. Through June 30, 2010, the Company operated exclusively in Australia. The Company was wholly subject to Australian income tax laws and regulations, which are administered by the Australian Taxation Office for the years ended June 30, 2010 and all prior years. On November 23, 2010, the Company was incorporated in the state of Delaware. In January 2011, the Company acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis with Propanc PTY LTD becoming a wholly owned subsidiary of the Company. As a result of these transactions, the Company is subject to the income tax laws of both the United States and Australia for the years ended June 30, 2013 through June 30, 2023. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21% to the income tax provision for the years ended June 30, 2023 and 2022 is as follows: SCHEDULE OF INCOME TAX PROVISION US June 30, 2023 June 30, 2022 Year Ended US June 30, 2023 June 30, 2022 Loss before Income taxes $ (2,790,407 ) $ (2,658,087 ) Taxes under statutory US tax rates $ (585,986 ) $ (558,198 ) Increase (decrease) in valuation allowance 861,178 339,334 Prior period adjustment (218,947 ) - Foreign tax rate differential (60,316 ) (64,349 ) Income tax rate change - 272,008 Other 4,071 11,205 Income tax (expense) benefit $ - $ - The Company reflects a tax benefit on its consolidated statement of operations and comprehensive income (loss) in 2023 and 2022 of $ 129,841 54,977 On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities consist of the following: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES June 30, 2023 June 30, 2022 Year Ended June 30, 2023 June 30, 2022 Deferred tax assets Warrant Derivative Liability $ 7,403 $ 7,403 Accrued Expenses 478,273 363,873 Prepaid Investor Services 575,021 427,318 Non-cash interest 758,797 709,936 Intangibles (Intellectual Property and Patent Cost) 321,557 293,260 Deferred Rent 4,550 4,198 Formation Expense 6,553 6,553 Net Operating Loss carryforward 8,910,873 8,759,357 Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Revalue of derivative liability 572,141 460,772 Stock Based Compensation 84,028 84,028 Total Deferred tax assets $ 11,679,818 $ 11,077,318 Deferred tax liabilities Research and Development $ (202,568 ) $ (170,435 ) Gain on extinguishment of debt 47,393 (259,470 ) Capital Raising Costs (369,033 ) (352,981 ) Total deferred tax liabilities $ (524,208 ) $ (782,886 ) Net deferred tax assets $ 11,155,610 $ 10,294,432 Valuation allowance (11,155,610 ) (10,294,432 ) Net deferred tax assets $ - $ - PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 At June 30, 2023, the Company had U.S. net operating loss carry forwards of $ 10,369,271 10.4 7.3 3.1 26% 25% 25% 26,933,305 No The Company applied the “more-likely-than-not” recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no Management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits. The Company follows ASC 740-10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise’s financial statements. Recognition involves a determination whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the consolidated statement of operations. As of June 30, 2023, the Company had no no The income tax returns filed for the tax years from inception will be subject to examination by the relevant taxing authorities.

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	12 Months Ended
	Jun. 30, 2023
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its certificate of incorporation, as amended (the “Certificate of Incorporation”), which increased the Company’s authorized capital stock. Such certificate of amendment increased the number of authorized shares of common stock from 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority-in-interest of the Company’s voting capital stock approved by written consent for the Company to file a certificate of amendment to its Certificate of Incorporation, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of common stock from 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005 On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand (1:1,000) PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 Of the total preferred shares authorized, 500,000 On March 15, 2023, the Company filed a certificate with the Secretary of State of Delaware (the “Certificate of Retirement”), effecting the retirement and cancellation of the Series A Preferred Stock to eliminate such Series A Preferred Stock. No none 500,000 Pursuant to a certificate of designation filed with the Secretary of State of the State of Delaware on June 16, 2015, five shares of preferred stock have been designated as Series B Preferred Stock, par value $ 0.01 One No Common Stock Shares issued under the Equity Lines Dutchess Capital Growth Fund LP On November 30, 2021, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Dutchess Capital Growth Fund LP, a Delaware limited partnership, (“Dutchess”), providing for an equity financing facility (the “Equity Line”). The Purchase Agreement provides that upon the terms and subject to the conditions in the Purchase Agreement, Dutchess is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Purchase Agreement, Dutchess will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Dutchess’ resale of any Common Stock purchased by Dutchess under the Equity Line. From time to time over the 36-month term of the Purchase Agreement, commencing on the trading day immediately following the date on which the Registration Statement becomes effective, the Company, in our sole discretion, may provide Dutchess with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 92% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 300% 250,000 The Company agreed to pay to Dutchess a commitment fee for entering into the Purchase Agreement of 1,000 1,000 20 20,000 20,000 20,000 Between April 5, 2022 and June 30, 2022, the Company issued an aggregate of 25,663 10 99,285 23,758 23,758 On July 13, 2022, the Company issued 14,337 2 24,711 23,758 Coventry Enterprises, LLC On November 3, 2022, the Company entered into a Common Stock Purchase Agreement (the “Coventry Purchase Agreement”) with Coventry providing for an equity financing facility (the “Coventry Equity Line”). The Purchase Agreement provides that, upon the terms and subject to the conditions in the Purchase Agreement, Coventry is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Coventry Purchase Agreement, Coventry will not be obligated to purchase shares of common stock unless and until certain conditions are met, including but not limited to a registration statement on Form S-1 becoming effective which registers Coventry’s resale of any common stock purchased by Coventry under the Coventry Equity Line. From time to time over the 36-month term of the Coventry Purchase Agreement, commencing on the trading day immediately following the date on which such registration statement becomes effective, the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Coventry Draw Down Notice”), to purchase a specified number of shares of common stock (each, a “Coventry Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Coventry Draw Down Notice (each, a “Coventry Draw Down Amount”) is to be determined by multiplying the Coventry Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of common stock equals 80% of the lowest volume weighted average price of the Common Stock during the 10 business days immediately preceding the Coventry Drawdown Notice date. The maximum number of shares of common stock requested to be purchased pursuant to any single Coventry Draw Down Notice cannot exceed the lesser of (i) 200% 250,000 9.99% PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Shares issued for conversion of convertible debt During the year ended June 30, 2022, the Company issued an aggregate of 96,960 7,326 10 40 599,148 36,154 2,250 657,125 19,572 7,326 During the year ended June 30, 2022, converted notes - principal of $ 1,000 8,000 28,572 19,572 2,069 335,677 During the year ended June 30, 2023, the Company issued an aggregate of 5,061,180 807,230 0.17 935,699 80,586 1,838 1,387,723 19,572 807,230 Included in the above conversion during the year ended June 30, 2023 were principal aggregate amount of convertible notes of $ 168,200 16,632 1,838 556,272 369,602 352,051 17,551 The Company has 3,764,903,510 Shares issued for services and accrued expenses On August 12, 2021, the Board approved the issuance of 2,800 84,000 2,800 30 87,920 3,920 84,000 On August 12, 2021, the Board approved the issuance of 167 167 50 7,883 7,883 In September 2021, the Company issued 2,820 40 104,611 104,611 On January 20, 2022, the Board approved the issuance of 667 667 30 20,000 20,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 On January 24, 2022, the Company issued 2,274 2,274 20 45,030 45,030 On February 17, 2022, the Board approved the issuance of 1,148 20 24,000 24,000 On April 13, 2022, the Company issued 3,834 3,834 12.2 46,771 46,771 On June 30, 2022, the Board approved the issuance of 12,271 12,271 3.70 45,403 45,403 12,271 On October 25, 2022, the Company issued 6,111 0.90 5,500 On November 16, 2022, the Company issued 73,301 0.07 51,311 51,311 On June 30, 2023, the Board approved the issuance of 608,423 608,423 0.135 82,137 82,137 608,423 Nathanielsz Cancellation Agreement On August 12, 2021, the Company entered into a Cancellation Agreement with James Nathanielsz (“Nathanielsz”), Chief Executive Officer and Director of the Company, whereby Nathanielsz agreed to cancel his cash compensation bonus award for fiscal year 2021, ended June 30, 2021, in exchange for common stock of the Company. The Company and Nathanielsz entered into an Amended and Restated Employment Agreement dated May 14, 2019 (the “Agreement”). Pursuant to the terms of the Agreement, Nathanielsz was eligible to earn an annual fiscal year cash performance bonus for each fiscal year of his employment period with the Company with a target performance bonus of 200% 78% 177,840 5,928 30 186,139 8,299 177,840 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Kenyon Cancellation Agreement On August 12, 2021, the Company entered into a Cancellation Agreement with Dr. Julian Kenyon (“Kenyon”), Chief Scientific Officer and Director of the Company, whereby Kenyon agreed to cancel of $ 102,600 3,420 30 107,388 4,788 102,600 Zelinger Amended and Restated Director Agreement On August 12, 2021, the Company entered into an Amended and Restated Director Agreement (the “Director Agreement”) with Josef Zelinger (“Zelinger”). Pursuant to the terms of the Director Agreement, the Company shall pay Zelinger a base salary of $ 250.00 184 2,800 84,000 2,800 30 87,920 3,920 84,000 Shares issued for exercise of warrants During the year ended June 30, 2022, the Company received aggregate gross proceeds of $ 625,000 16 40,000 16 During the year ended June 30, 2023, the Company received aggregate gross proceeds of $ 475,000 12 40,000 12 During the year ended June 30, 2022, the Company issued 56,800 0.284 200,000 0.001 During the year ended June 30, 2023, the Company issued an aggregate of 559,999 206,000 0.97 200,000 0.001 The Alternate Cashless Exercise provision, for a cashless conversion at the holder’s option, is available should the trading price of the Company’s common stock fall below $ 200,000 70% 466,273 700,340 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Shares issued in connection with a convertible note On November 3, 2022, the Company entered into a securities purchase agreement with Coventry, pursuant to which Coventry purchased a promissory note from the Company in the aggregate principal amount of $ 125,000 75,000 37,500 Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 0.078 0.039 0.117 0.117 4,250,000 497,240 248,620 0.06 248,620 Stock Options A summary of the Company’s stock option activity during the years ended June 30, 2023 and 2022 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Options Price Per Share Outstanding at June 30, 2021 0.059 $ 13,730,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2022 0.059 $ 4,533,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2023 0.059 $ 4,533,000 Exercisable at June 30, 2023 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 5.88 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ - On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 During the years ended June 30, 2023 and 2022, the Company recognized stock-based compensation of $ 0 72,513 0 No PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Stock Warrants The following table summarizes common stock warrant activity for the years ended June 30, 2023 and 2022: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Warrants Price Per Share Outstanding at June 30, 2021 121 $ 179,630 Issued - - Exercised (16 ) 42,860 Forfeited - - Expired - - Outstanding at June 30, 2022 105 $ 200,270 Issued 3,305 10 Exercised (13 ) 52,081 Forfeited (1 ) 2,000,000 Expired - - Outstanding at June 30, 2023 3,396 * $ 5,440 Exercisable at June 30, 2023 3,379 $ 5,467 Outstanding and Exercisable: Weighted average remaining contractual term 2.14 Aggregate intrinsic value $ - * The total warrants of 3,396 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 17 17 Series C warrants 64 47 Warrants with no class designation 3,305 3,305 Total 3,396 3,379 In connection with the issuance of shares on April 3, 2020, the Company closed on a transaction related to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into on March 30, 2020, whereby an investor purchased from the Company, 7.5 units, each consisting of (i) 1.5 shares of the Company’s common stock, or pre-funded warrants upon Investor’s election due to the 4.99% blocker provision and (ii) 1.5 warrants to purchase one share of Common Stock (“Series A Warrants”, and collectively with the Common Stock the “Units”). 64 64 10 100 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Series A Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series A Warrants to purchase up to 11 200,000 3 the Series A Warrants contain a provision for a cashless conversion at the Holder’s option should the trading price of the Common Stock fall below $200,000, per share calculated based on the difference between the exercise price of the Series A Warrant and 70% of the Market Price, as defined therein (the” Alternate Cashless Exercise”). The Alternate Cashless Exercise price is $0.001. Series B Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series B Warrants to purchase up to 64 38 10 4 4 40,000 3 Series C Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series C Warrants to purchase up to 64 3 200,000 Letter Agreement to Extend Termination Dates. On March 8, 2023, the Company agreed with the holder of Series B Warrants (the “Holder”) pursuant to a letter agreement to exercise up to $ 250 1. Effective upon the execution of such letter agreement, the Holder will exercise 4 150,000 4 2. Within 5 business days’ written notice to the Holder from the Company of receipt of approval by the Financial Industry Regulatory Authority, Inc. (“FINRA”) of the Company’s next anticipated reverse stock split, an additional $ 100,000 3 As an inducement to exercise the Existing Warrants, the Company agreed to extend the termination date of the Existing Warrants and the Series A Warrants held by the Holder to March 27, 2025, and to extend the termination date of the Series C Warrants held by the Holder to the third anniversary of the last vesting date of such warrants, effective upon the exercise of the first $ 150,000 In accordance with ASC 815-40-35-17(c), the effect of a modification or an exchange of an equity classified freestanding written call option shall be measured as the difference between the fair value of the modified instrument and the fair value of that instrument immediately before it is modified. The Company recognized the effect of the modifications of the warrants above that is directly attributable to an actual equity offering as an equity issuance cost which amount is not material. The modified warrants are determined to be equity classified, accordingly, the incremental fair value and equity issuance cost were both recognized in additional paid in capital and therefore, there was no effect in equity and such value is de minimis. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Warrants Issued to Vendors On August 16, 2022, the Company entered into an agreement with a certain consultant to provide services over a three-month period in exchange for 1,000 10 August 16, 2025 2,408 2.60 10 zero 3.00 3.19% 236% 2,408 On August 16, 2022, the Company and a third-party investor relations consultant agreed to settle an outstanding payable of $ 23,050 2,305 10 5,551 2.60 10 zero 3.00 3.19% 236% 17,499 Exercise of Warrants During the year ended June 30, 2022, the Company received aggregate gross proceeds of $ 625,001 16 16 During the year ended June 30, 2022, the Company issued 56,800 0.284 During the year ended June 30, 2023, the Company received aggregate gross proceeds of $ 475,000 12 40,000 12 During the year ended June 30, 2023, the Company issued an aggregate of 559,999 206,000 0.97 200,000 0.001

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “UK University”), whereby the Company and the UK University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the UK University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property, while agreeing to pay royalties of 2% 5% Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 Euros ($ 59,508 USD) in year one and a maximum of 40,000 Euros ($ 45,775 USD) in year two. Additionally, in exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 2% of net revenues to the University. On October 1, 2020, the Company entered into another two-year collaboration agreement with the University to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 30,000 Euros ($ 35,145 USD), which were paid in four installment payment of 5,000 Euros in November 2020, 5,000 Euros ($ 5,858 ) in March 2021, 10,000 Euros ($ 11,715 ) in December 2021 and 10,000 Euros ($ 11,715 ) in September 2022. Additionally, the University agreed to hire and train a doctoral student for this project and the Company agreed to pay the University 25,837 Euros ($ 30,268 USD). In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 2% of net revenues to the University. On July 27, 2022, the Company entered into a two-year research agreement with the University to provide certain research and experiment services to the Company. One of the Company’s Scientific Advisory Board is the lead joint researcher of the University. In exchange for full ownership of the intellectual property, the Company agreed to pay royalties of 1% of net revenues each to two members of the Scientific Advisory Board. In consideration of such services, the Company agreed to pay the University approximately 53,200 Euros ($ 53,806 USD) payable as follows: - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments was on September 1, 2022, and the estimated length of time for completion is 24 months. As of June 30, 2023 and 2022, the Company has $ 18,056 14,364 no Consulting Agreement On October 1, 2021, the Company entered into a consulting agreement (the “Consulting Agreement”) with a consultant who will assist in the development of the Company’s business and financing activities. The consultant will serve initially as an independent contractor, and upon certain mutually agreed upon conditions being met, will be appointed Vice Chairman, President and Interim CFO. The term of the Consulting Agreement was for three years commencing on October 1, 2021 and can be terminated by either party upon 30 day written notice. The monthly payment per the Consulting Agreement was $ 7,000 1,148,326 On July 1, 2022, the Company and a consultant agreed to extend the term of a consulting agreement from July 1, 2022 to June 30, 2023 to provide media-related services for a monthly fee of $ 50,000 9.9% 9.9% 73,301 608,423 0 Operating Leases On May 4, 2022, the Company entered in a three 3,000 2,176 66,201 66,201 8 ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET June 30, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (27,213 ) (3,678 ) Right-of-use asset, net $ 38,988 $ 62,523 Operating lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY June 30, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Reduction of lease liability (25,418 ) (3,277 ) Less: office lease, current portion (21,505 ) (20,605 ) Long term portion of lease liability $ 19,278 $ 42,319 Remaining future minimum lease payments under the non-cancelable operating lease at June 30, 2023 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2024 $ 23,990 Fiscal Year 2025 19,992 Imputed interest (3,199 ) Total operating lease liability $ 40,783 The weighted average remaining lease term for the operating lease is 1.77 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	12 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS AND BALANCES	NOTE 10 – RELATED PARTY TRANSACTIONS AND BALANCES Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of June 30, 2023 and 2022, the Company owed its former director a total of $ 29,630 30,746 As of June 30, 2023 and 2022, the Company owed its former director a total of $ 49,314 51,171 Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease had a five-year 39,600 28,325 3,600 2,575 198,000 141,629 Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022. three-year 3,000 2,176 158,129 105,377 122,129 84,452 28,841 28,366 Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz’s employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5% 200% 300,000 205,680 400,000 274,240 400,000 309,313 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive, part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 Pursuant to a February 25, 2016 board resolution, James Nathanielsz is paid $ 4,481 3,205 7,689 5,577 On August 12, 2021, the Board approved a bonus of $ 177,840 221,890 166,418 422,610 316,957 177,840 5,928,000 140,000 96,810 144,166 99,691 181,324 125,386 73,387 48,905 107,937 71,929 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Amended and Restated Employment Agreement On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with Mr. Nathanielsz for a term of three 400,000 309,313 0.04 4,675,000 110% 4,250,000 0.04 0.04 10 0.04 0.04 On October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with Mr. Nathanielsz, effective as of July 1, 2022, (the “2022 Effective Date”). The Amended Agreement provides Mr. Nathanielsz with a base salary of $ 600,000 414,900 100% 200% Amended and Restated Employment Agreement On May 14, 2019, the Company entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three 54,000 41,580 0.02 4,250,000 100% 0.02 0.02 10 0.02 0.02 On August 12, 2021, pursuant to a Cancellation Agreement, Mr. Kenyon agreed to cancel accrued salaries of $ 102,600 3,420 96,000 64,627 82,500 56,050 Intercompany Loans All intercompany loans were made by the parent to the Company’s subsidiary, Propanc PTY LTD, none of which has been repaid as of June 30, 2023. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the consolidated balance sheet as accumulated other comprehensive income. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	12 Months Ended
	Jun. 30, 2023
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 11 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through June 30, 2023. In fiscal year 2022, the Company primarily relied on funding from three convertible debt lenders and received net proceeds after deductions of $ 73,500 766,500 160,000 360,000 246,500 21 47 32 In fiscal 2023, the Company primarily relied on funding from five convertible debt lenders and received net proceeds after deductions of $ 79,111 101,250 189,000 150,000 50,000 100,000 17 32 25 8 18 Receivable Concentration As of June 30, 2023 and 2022, the Company’s receivables were 100 Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Republic of Korea, India and Brazil. In Canada and Mexico, the patent applications have been accepted as of this fiscal year 2023. In 2016 and early 2017, the Company filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application entered national phase in August 2018. A third PCT application entered the national phase in October 2018. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 62 granted, allowed, or accepted patents and 14 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of June 30, 2023 and 2022, the Company’s operations are based in Camberwell, Australia; however, the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales, for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2023 and 2022, there has been no activity within this entity. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	12 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 12 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 75,300 79,000 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at June 30, 2023, the last trading day of the period ended June 30, 2023, was $ 0.135 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during Volatility 228.29 256.02 Expected Remaining Term (in years) 0.22 0.28 Risk Free Interest Rate 3.13 4.42 Expected dividend yield None June 30, 2023 June 30, 2022 Volatility 334.56 % 228 % Expected remaining term 0.01 0.73 0.01 Risk-free interest rate 5.24 % 1.28 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2023: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 423,209 $ — $ — $ 423,209 Total $ 423,209 $ — $ — $ 423,209 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2022: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262 The following is a roll forward for the years ended June 30, 2023 and 2022 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2021 $ 54,220 Initial fair value of embedded conversion option derivative liability recorded as debt discount - Gain on debt extinguishment (2,069 ) Change in fair value included in statements of operations 99,111 Balance at June 30, 2022 151,262 Beginning balance 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Gain on debt extinguishment (352,051 ) Change in fair value included in statements of operations 530,330 Balance at June 30, 2023 $ 423,209 Ending balance $ 423,209

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS Loans Payable July 5, 2023, the Company and an institutional investor affiliated with one of our directors, Josef Zelinger, entered into a letter agreement, pursuant to which such investor loaned the Company an aggregate of $ 230,000 153,256 three July 5, 2026 10 15,000,000 0.01 A portion of the proceeds of such loan were used to repay an outstanding balance of approximately $ 143,000 Promissory Note On August 15, 2023, the Company issued to an institutional investor (the “August 2023 Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $ 120,000 132,000 November 15, 2023 10 18 The Company has the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023, unless the Company and the Lender agree to otherwise effect repayment. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Issuance of convertible notes 1800 Diagonal Lending, LLC Securities Purchase Agreements On June 29, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), which closed on July 6, 2023, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 6, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 65,000 5,000 June 29, 2024 On July 19, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 19, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 45,000 5,000 July 19, 2024 On August 16, 2023, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC pursuant to which 1800 Diagonal purchased a convertible promissory note (the “August 16, 2023 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 55,000 5,000 August 16, 2024 The 1800 Diagonal Notes bear interest at a rate of 8 During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above notes shall be equal to a 35 9.99 The above notes contains certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 Failure to deliver shares of common stock upon conversion of the above 1800 Diagonal notes within three business days of notice of conversion will result in the Company paying a penalty of $ 1,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Upon certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company must pay 1800 Diagonal 150 GS Capital Partners, LLC Securities Purchase Agreement On August 23, 2023, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 77,500 5,000 2,500 The maturity date of the GS Capital Note is February 23, 2024 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note. During the first 60 to 180 days following the date of this note, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note issued to GS Capital, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest shall accrue at a default interest rate of 24 250 th 500 th 20 The above GS Capital note will be bifurcated from the embedded conversion option which shall be recorded as derivative liabilities at fair value. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 Equity Line Agreement On July 20, 2023, the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with an institutional investor (the “Investor”) providing for an equity financing facility, pursuant to which Company has the option to request that the Investor commit to purchase up to $ 5,000,000 0.001 24 Pursuant to the Equity Line Agreement, purchases of Shares cannot occur unless and until certain conditions are met, including but not limited to, the SEC declaring the Registration Statement effective, and the maximum number of Shares that may be purchased pursuant to a Drawdown Notice cannot exceed the lesser of (i) 200% of the average daily traded value of the Common Stock during the five (5) business days immediately preceding a Drawdown Notice or (ii) $200,000; provided that in no event may a Drawdown Notice be for less than $5,000, exceed 52,500,000 Shares or cause the Investor’s ownership to exceed 4.99% of the outstanding number of shares of Common Stock immediately prior to the issuance of such Shares. The actual amount of proceeds that the Company will receive in connection with each Drawdown Notice is determined under the Equity Line Agreement by multiplying the number of Shares to be sold by the applicable purchase price per share, which is equal to 85% of the lowest traded price of the Common Stock during the 7 business days immediately following the Clearing Date, less Clearing Costs (as each such term is defined in the Equity Line Agreement). Additionally, in connection with the Equity Line Agreement, the Company and the Investor entered into a registration rights agreement, dated July 20, 2023 (the “Registration Rights Agreement”), pursuant to which the Company agreed to register the maximum number of Shares within 45 days of the date of the Registration Rights Agreement, subject to any comments from the SEC and applicable laws, rules and regulations. Exercise of warrants The Company issued an aggregate of 2,282,000 shares of common stock from the alternate cashless exercise of 0.011 Series A warrants. The Company recognized the value of the effect of a down round feature in such warrants when triggered. Upon the occurrence of the triggering event that resulted in a reduction of the strike price, the Company measured the value of the effect of the feature as the difference between the fair value of the warrants without the down round feature or before the strike price reduction and the fair value of the warrants with a strike price corresponding to the reduced strike price upon the down round feature being triggered. Accordingly, the Company recognized deemed dividend of $ 142,575 and a corresponding reduction of income available to common stockholders upon the alternate cashless exercise of these warrants. Shares issued for conversion of convertible debt From July 1, 2023 through September 18, 2023, the Company issued an aggregate of 4,898,307 0.02 98,954 7,071 1,277 21,737

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) is based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware, and in January 2011, to reorganize the Company, all of the outstanding shares of Propanc PTY LTD were acquired on a one-for-one basis by Propanc Health Group Corporation, with Propanc PTY LTD becoming a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed another wholly-owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2023, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to reflect the Company’s stage of operations and development better. In July 2020, a world-first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 62 granted, allowed, or accepted patents and 14 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. On May 1, 2023, the Company filed a certificate of amendment to its certificate of incorporation, as amended, to effect a one-for-one thousand The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through June 30, 2023.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly-owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency, which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of June 30, 2023 and 2022, the Company recognized a cumulative exchange gain (loss) of approximately $ 648,000 1,289,000 As of June 30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES June 30, 2023 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6664 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6732 0.7253 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2023 and 2022 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Beginning balance, June 30, 2021 $ 1,085,204 Foreign currency translation gain 149,345 Balance, June 30, 2022 1,234,549 Foreign currency translation gain 60,327 Ending balance, June 30, 2023 $ 1,294,876 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts, as applicable, are reflected as a current liability on the balance sheets. There were no
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through June 30, 2023 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Employee Benefit/Liability	Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months.
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2023 and 2022, the Company was owed $ 2,867 2,342
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into shares of the Company’s common stock, par value $ 0.001 Distinguishing Liabilities from Equity PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 247,919 256,052 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. During each of the fiscal years ended June 30, 2023 and 2022, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 129,841 54,977
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred.
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 months or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company’s previously reported financial position or results of operations and relate to the presentation of accrued interest separately on the consolidated balance sheet, of which $ 57,822
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS	Basic and Diluted Net Loss Per Common Share Basic net loss per share of common stock is computed by dividing the net loss by the weighted average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants, restricted stock units and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per-share amounts for all periods presented are identical. Each holder of the notes and warrants has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS June 30, 2023 June 30, 2022 Stock Options 0.06 0.06 Warrants with no designations 90 105 Series A Warrants as if converted at alternate cashless exercise prices 1,996,625,990 - Series B Warrants 16 - Series C Warrants as if converted at alternate cashless exercise prices * 9,473,999,953 - Unvested restricted stock units 0.06 0.06 Convertible Debt 5,991,195 127,062 Total 11,476,617,244.12 127,167.12 * Only convertible ratably upon exercise of Series B Warrants PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term with the exception of those disclosed below. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on its consolidated financial statements.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF TRANSACTION EXCHANGE RATES	As of June 30, 2023 and 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSACTION EXCHANGE RATES June 30, 2023 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6664 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6732 0.7253
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS	Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2023 and 2022 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Beginning balance, June 30, 2021 $ 1,085,204 Foreign currency translation gain 149,345 Balance, June 30, 2022 1,234,549 Foreign currency translation gain 60,327 Ending balance, June 30, 2023 $ 1,294,876
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS June 30, 2023 June 30, 2022 Stock Options 0.06 0.06 Warrants with no designations 90 105 Series A Warrants as if converted at alternate cashless exercise prices 1,996,625,990 - Series B Warrants 16 - Series C Warrants as if converted at alternate cashless exercise prices * 9,473,999,953 - Unvested restricted stock units 0.06 0.06 Convertible Debt 5,991,195 127,062 Total 11,476,617,244.12 127,167.12 * Only convertible ratably upon exercise of Series B Warrants

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following as of June 30: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2023 2022 Office equipment at cost $ 25,432 $ 28,623 Less: Accumulated depreciation (25,130 ) (26,600 ) Total property, plant, and equipment $ 302 $ 2,023

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Jun. 30, 2023
Convertible Notes
SCHEDULE OF CONVERTIBLE NOTES	The Company’s convertible notes outstanding at June 30, 2023 and 2022 were as follows: SCHEDULE OF CONVERTIBLE NOTES June 30, 2023 June 30, 2022 Convertible notes and debenture $ 338,362 $ 644,980 Unamortized discounts (38,994 ) (31,669 ) Premium, net 91,171 313,127 Convertible notes, net $ 390,539 $ 926,438

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX PROVISION	The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21% to the income tax provision for the years ended June 30, 2023 and 2022 is as follows: SCHEDULE OF INCOME TAX PROVISION US June 30, 2023 June 30, 2022 Year Ended US June 30, 2023 June 30, 2022 Loss before Income taxes $ (2,790,407 ) $ (2,658,087 ) Taxes under statutory US tax rates $ (585,986 ) $ (558,198 ) Increase (decrease) in valuation allowance 861,178 339,334 Prior period adjustment (218,947 ) - Foreign tax rate differential (60,316 ) (64,349 ) Income tax rate change - 272,008 Other 4,071 11,205 Income tax (expense) benefit $ - $ -
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES June 30, 2023 June 30, 2022 Year Ended June 30, 2023 June 30, 2022 Deferred tax assets Warrant Derivative Liability $ 7,403 $ 7,403 Accrued Expenses 478,273 363,873 Prepaid Investor Services 575,021 427,318 Non-cash interest 758,797 709,936 Intangibles (Intellectual Property and Patent Cost) 321,557 293,260 Deferred Rent 4,550 4,198 Formation Expense 6,553 6,553 Net Operating Loss carryforward 8,910,873 8,759,357 Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Revalue of derivative liability 572,141 460,772 Stock Based Compensation 84,028 84,028 Total Deferred tax assets $ 11,679,818 $ 11,077,318 Deferred tax liabilities Research and Development $ (202,568 ) $ (170,435 ) Gain on extinguishment of debt 47,393 (259,470 ) Capital Raising Costs (369,033 ) (352,981 ) Total deferred tax liabilities $ (524,208 ) $ (782,886 ) Net deferred tax assets $ 11,155,610 $ 10,294,432 Valuation allowance (11,155,610 ) (10,294,432 ) Net deferred tax assets $ - $ -

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	12 Months Ended
	Jun. 30, 2023
Equity [Abstract]
SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY	A summary of the Company’s stock option activity during the years ended June 30, 2023 and 2022 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Options Price Per Share Outstanding at June 30, 2021 0.059 $ 13,730,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2022 0.059 $ 4,533,000 Issued - - Exercised - - Expired - - Outstanding at June 30, 2023 0.059 $ 4,533,000 Exercisable at June 30, 2023 0.059 $ 4,533,000 Outstanding and Exercisable: Weighted average remaining contractual term 5.88 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ -
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes common stock warrant activity for the years ended June 30, 2023 and 2022: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Warrants Price Per Share Outstanding at June 30, 2021 121 $ 179,630 Issued - - Exercised (16 ) 42,860 Forfeited - - Expired - - Outstanding at June 30, 2022 105 $ 200,270 Issued 3,305 10 Exercised (13 ) 52,081 Forfeited (1 ) 2,000,000 Expired - - Outstanding at June 30, 2023 3,396 * $ 5,440 Exercisable at June 30, 2023 3,379 $ 5,467 Outstanding and Exercisable: Weighted average remaining contractual term 2.14 Aggregate intrinsic value $ - * The total warrants of 3,396
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10 10 Series B warrants 17 17 Series C warrants 64 47 Warrants with no class designation 3,305 3,305 Total 3,396 3,379

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT OF USE ASSET	ROU is summarized below: SCHEDULE OF RIGHT OF USE ASSET June 30, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (27,213 ) (3,678 ) Right-of-use asset, net $ 38,988 $ 62,523
SCHEDULE OF OPERATING LEASE LIABILITY	Operating lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY June 30, 2023 June 30, 2022 Office lease $ 66,201 $ 66,201 Reduction of lease liability (25,418 ) (3,277 ) Less: office lease, current portion (21,505 ) (20,605 ) Long term portion of lease liability $ 19,278 $ 42,319
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under the non-cancelable operating lease at June 30, 2023 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2024 $ 23,990 Fiscal Year 2025 19,992 Imputed interest (3,199 ) Total operating lease liability $ 40,783

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations into during Volatility 228.29 256.02 Expected Remaining Term (in years) 0.22 0.28 Risk Free Interest Rate 3.13 4.42 Expected dividend yield None June 30, 2023 June 30, 2022 Volatility 334.56 % 228 % Expected remaining term 0.01 0.73 0.01 Risk-free interest rate 5.24 % 1.28 % Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 423,209 $ — $ — $ 423,209 Total $ 423,209 $ — $ — $ 423,209 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2023 and 2022 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2022: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	The following is a roll forward for the years ended June 30, 2023 and 2022 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2021 $ 54,220 Initial fair value of embedded conversion option derivative liability recorded as debt discount - Gain on debt extinguishment (2,069 ) Change in fair value included in statements of operations 99,111 Balance at June 30, 2022 151,262 Beginning balance 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Gain on debt extinguishment (352,051 ) Change in fair value included in statements of operations 530,330 Balance at June 30, 2023 $ 423,209 Ending balance $ 423,209

SCHEDULE OF TRANSACTION EXCHANG

SCHEDULE OF TRANSACTION EXCHANGE RATES (Details)	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6664	0.6915
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6732	0.7253

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Accounting Policies [Abstract]
Beginning balance	$ 1,234,549	$ 1,085,204
Foreign currency translation, gain	60,327	149,345
Ending balance	$ 1,294,876	$ 1,234,549

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE (Details)	Jun. 30, 2023
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS (Details) - shares		12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		11,476,617,244.12	127,167.12
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		90	105
Series A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		1,996,625,990
Series B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		16
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	[1]	9,473,999,953
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		0.06	0.06
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		5,991,195	127,062
[1]Only convertible ratably upon exercise of Series B Warrants

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)		12 Months Ended
	May 01, 2023	Jun. 30, 2023	Jun. 30, 2022
Short-Term Debt [Line Items]
Reverse stock split	one-for-one thousand
Cash and cash equivalents		$ 0	$ 0
Value added tax receivable		$ 2,867	$ 2,342
Common stock, par value		$ 0.001	$ 0.001
Research and development costs		$ 247,919	$ 256,052
Research and development tax credit		129,841	54,977
Interest Payable		$ 44,709	57,822
Beneficial ownership conversion description		Each holder of the notes and warrants has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ abilities to increase such limitation to 9.99% upon 60 days’ notice to the Company), and certain notes may not be converted during the certain specified time period from the date of issuance
Beneficial ownership percentage		4.99%
Intercompany Loans [Member]
Short-Term Debt [Line Items]
Foreign currency transaction, gain		$ 648,000	$ 1,289,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 2,660,566	$ 2,658,087
Net Cash Provided by (Used in) Operating Activities	1,105,251	1,436,304
Working capital deficit	3,139,190
Stockholders equity	3,117,179	3,023,649	$ 3,067,573
Retained earnings accumulated deficit	$ 64,684,732	$ 61,557,893

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 25,432	$ 28,623
Less: Accumulated depreciation	(25,130)	(26,600)
Total property, plant, and equipment	$ 302	$ 2,023

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 1,665	$ 1,993

DUE TO FORMER DIRECTOR - RELA_2

DUE TO FORMER DIRECTOR - RELATED PARTY (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Due to related parties current	$ 29,630	$ 30,746

LOANS (Details Narrative)

LOANS (Details Narrative) - USD ($)		12 Months Ended
	Oct. 03, 2019	Jun. 30, 2023	Jun. 30, 2022	Nov. 30, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Loans payable		$ 65,280
Debt instrument face amount		168,200	1,000
Gain on extinguishment of debt		25,969	(17,503)
Interest payable current and non current		$ 16,632	8,000
Crown Bridge Partners, LLC [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt instrument interest rate stated percentage		15%
Debt instrument face amount		$ 65,280
Interest payable current and non current		$ 35,722
Securities Purchase Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Debt instrument interest rate stated percentage		18%
Interest payable current and non current		$ 22,749
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Convertible debt	$ 65,280
Maturity date	Oct. 03, 2020
Debt instrument interest rate stated percentage	15%
Debt instrument face amount		65,280	65,280	$ 9,600
Gain on extinguishment of debt	$ 43,520	43,520
Interest payable current and non current		35,722	25,930
Related Party [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Loans payable		49,314	51,171
Directors and Officer [Member] | Related Party [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Loans payable		$ 49,314	$ 51,171

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Convertible Notes
Convertible notes and debenture	$ 338,362	$ 644,980
Unamortized discounts	(38,994)	(31,669)
Premium, net	91,171	313,127
Convertible notes, net	$ 390,539	$ 926,438

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative) - USD ($)																																		1 Months Ended	12 Months Ended
	Feb. 14, 2023	Nov. 03, 2022	Nov. 03, 2022	Oct. 06, 2022	Sep. 21, 2022	Sep. 21, 2022	Aug. 15, 2022	Aug. 12, 2022	Jun. 30, 2022	May 12, 2022	Apr. 12, 2022	Mar. 29, 2022	Mar. 07, 2022	Jan. 04, 2022	Dec. 07, 2021	Nov. 26, 2021	Oct. 21, 2021	Sep. 22, 2021	Aug. 19, 2021	Mar. 16, 2021	Jan. 05, 2021	Dec. 10, 2020	Dec. 10, 2020	Dec. 09, 2020	Dec. 02, 2020	Sep. 16, 2020	Sep. 12, 2020	Oct. 03, 2019	Oct. 03, 2019	Oct. 01, 2019	Sep. 04, 2019	Aug. 30, 2019	Aug. 10, 2017	Aug. 30, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020	Mar. 15, 2021	Nov. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Lowest trading price percentage																																			4.99%
Embedded derivative fair value of embedded derivative liability									$ 151,262																										$ 423,209	$ 151,262
Convertible debt principal amount									1,000																										168,200	1,000
Interest payable current and non current									8,000																										16,632	8,000
Liabilities									3,105,300																										3,177,507	3,105,300
Gain on extinguishment of debt																																			25,969	(17,503)
Proceeds from convertible debt																																			590,250	766,500
Settled debt premium									313,127																										91,171	313,127
Original issue discount									31,669																										38,994	31,669
Penalty amount																																			30,000
Premium Issued									644,980																										338,362	644,980
Original issue discounts amount																																			79,111	73,500
Additional debt issued																																			1,387,723	657,125
Amortization of debt discount																																			202,952	47,971
Conversion stock amount																																			$ 411,111	335,677
Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Interest payable current and non current									716																											716	$ 39,536	$ 43,176
Crown Bridge Partners, LLC [Member]
Debt interest rate																																			15%
Convertible debt principal amount																																			$ 65,280
Interest payable current and non current																																			35,722
1800 Diagonal Lending [Member]
Interest payable current and non current									4,700																										14,800	4,700
ONE44 Capital LLC [Member]
Interest payable current and non current									2,873																										24,255	2,873
Settled debt premium																																			289,459
GS Capital Partners, LLC [Member]
Interest payable current and non current																																			2,945
Coventry Enterprises LLC Securities Purchase Agreement [Member]
Monthly payment amount		$ 19,643
August 10, 2017 Consulting Agreement [Member]
Convertible debt outstanding balance																																	$ 310,000
Debt interest rate																																	10%
Convertible debt principal amount																																	$ 750		79,000	1,000		500
Lowest trading price percentage																																	65%
Maturity date																																	Aug. 10, 2019
Accrued liabilities current and non current																																						5,248				$ 155,000	$ 155,000
Debt instrument debt default interest rate																																	18%
Embedded derivative fair value of embedded derivative liability																																	$ 578,212
Convertible debt principal amount																																						8,500			$ 9,000
Interest payable current and non current									8,000																										9,543	8,000		22,168
August 10, 2017 Consulting Agreement [Member] | GS Capital Partners, LLC [Member]
Convertible debt principal amount																																			89,200
August 10, 2017 Consulting Agreement [Member] | Settlement and Mutual Release Agreement [Member]
Convertible debt outstanding balance																																	79,000		$ 0				$ 100,000
Accrued liabilities current and non current																																							25,000
Convertible debt principal amount																																							8,500
Interest payable current and non current																																	$ 10,185						23,262
Liabilities																																							$ 56,762
Gain on extinguishment of debt																																					43,238
August 10, 2017 Consulting Agreement [Member] | Consultant [Member]
Convertible debt principal amount																																									161,000	140,000
Interest payable current and non current																																									$ 19,418	$ 10,764
Securities Purchase Agreement [Member]
Debt interest rate																																			18%
Interest payable current and non current																																			$ 22,749
Original issue discount									452,308																										232,674	452,308
Debt instrument debt default interest rate					60%			60%
Amount of convertible debt outstanding with penalty																																			144,951
Amortization of debt discount																																			210,278	73,500
Securities Purchase Agreement [Member] | August 2019 Auctus Note [Member]
Debt interest rate																																24%		24%
Securities Purchase Agreement [Member] | September 22, 2021 Geneva Roth [Member]
Interest payable current and non current																																					3,120
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Convertible debt outstanding balance									0																											0
Debt interest rate																																10%		10%
Convertible debt principal amount																																				32,848	326,117	191,035
Lowest trading price percentage																																60%
Maturity date																																Aug. 30, 2020
Debt instrument debt default interest rate																																24%
Convertible debt principal amount																															$ 550,000	$ 550,000		$ 550,000
Interest payable current and non current									0																							15,000		15,000		0	0	486
Legal fees and due diligence expenses																															5,000
Diligence fees																															40,000
Proceeds from convertible debt																															$ 505,000
Settled debt premium									21,899																							$ 366,667		$ 366,667		21,899	217,411	127,356
Ownership limitations																																125%		4.99%
Debt instrument description																																Upon the holder’s election to convert accrued interest, default interest or any penalty amounts as stipulated, the Company may elect to pay those amounts in cash. The note may also be prepaid by the Company at any time between the date of issuance and August 13, 2020 at 135% multiplied by the sum of (a) the then outstanding principal amount plus (b) accrued and unpaid interest plus (c) default interests, if any.
Fair value adjustment of warrants																																$ 375,905
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | First Warrant [Member]
Warrants and rights outstanding																																2,250,000		$ 2,250,000
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Second Warrant [Member]
Warrants and rights outstanding																																$ 3,330,000		$ 3,330,000
Purchase of warrants																																300		300
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Third Warrant [Member]
Warrants and rights outstanding																																$ 4,500,000		$ 4,500,000
Purchase of warrants																																225		225
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Debt interest rate																												15%	15%
Maturity date																												Oct. 03, 2020
Debt instrument debt default interest rate																													15%
Convertible debt principal amount									65,280																										65,280	65,280				$ 9,600
Interest payable current and non current									$ 25,930																										35,722	25,930
Gain on extinguishment of debt																												$ 43,520							43,520
Settled debt premium																												72,000	$ 72,000						13,889					6,400
Debt instrument description																													The conversion price of the Crown Bridge Note was equal to 60% (representing a 40% discount) of the lowest closing bid price of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion under such note, including the day upon which such notice was received.
Original issue discount																												5,000	$ 5,000
Unissued shares conversion																										15
Equity conversion																																								$ 16,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate																													110%
Ownership limitations																													4.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate																													150%
Ownership limitations																													9.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | August 2019 Auctus Note [Member]
Convertible debt principal amount																																						42,720
Interest payable current and non current																																						7,232
Settled debt premium																																						28,480
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member]
Convertible debt principal amount																												108,000	$ 108,000									65,280
Proceeds from convertible debt																													$ 100,000
Debt instrument principal payment																												$ 3,000
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member]
Convertible debt principal amount																																						101,000
Interest payable current and non current																																					0	5,082
Settled debt premium																																					20,000	67,333
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member]
Debt interest rate																														8%
Maturity date																														Oct. 01, 2020
Convertible debt principal amount																														$ 131,000							30,000	30,000
Interest payable current and non current																																					3,877	1,776
Proceeds from convertible debt																														125,000
Debt instrument principal payment																														$ 6,000
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member]
Debt interest rate																						8%	8%
Maturity date																						Dec. 10, 2021
Debt instrument debt default interest rate																								24%
Convertible debt principal amount																						$ 131,000	$ 131,000
Proceeds from convertible debt																							125,000
Settled debt premium																						$ 174,666	174,666
Debt instrument description																						The conversion price for the above GW Holdings notes was equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion was received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the GW Holdings to the Company.
Debt instrument principal payment																						$ 6,000
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member] | Minimum [Member]
Debt instrument debt default interest rate																											110%
Ownership limitations																						4.99%
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member] | Maximum [Member]
Debt instrument debt default interest rate																											150%
Ownership limitations																						9.99%
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | December 02 2020 Geneva Roth [Member]
Debt interest rate																									8%
Maturity date																									Dec. 02, 2021
Convertible debt principal amount																									$ 78,000
Original issue discount																									$ 3,000
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | January 5, 2021 Geneva Roth [Member]
Debt interest rate																					8%
Maturity date																					Jan. 05, 2022
Convertible debt principal amount																					$ 68,500
Original issue discount																					$ 3,500
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | March 16, 2021 Geneva Roth [Member]
Debt interest rate																				8%
Maturity date																				Mar. 16, 2022
Convertible debt principal amount																				$ 63,500
Original issue discount																				$ 3,500
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | August 19, 2021 Geneva Roth [Member]
Debt interest rate																			8%
Convertible debt principal amount																			$ 103,750
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member]
Debt interest rate																		8%
Maturity date																		Sep. 22, 2022	Aug. 19, 2022
Debt instrument debt default interest rate																		35%
Convertible debt principal amount																		$ 63,750
Settled debt premium																		$ 203,269
Debt instrument description																		The conversion price for the above Geneva Roth notes was equal to a 35% discount of the market price based on the average of the lowest three trading prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion. Notwithstanding the foregoing, Geneva Roth shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Geneva Roth and its affiliates, exceeds 9.99% of the outstanding shares of the Company’s common stock.
Original issue discount																		$ 3,750	$ 3,750
Debt outstanding principal percentage																		22%
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member] | Minimum [Member]
Debt instrument debt default interest rate																		110%
Ownership limitations																		9.99%
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member] | Maximum [Member]
Debt instrument debt default interest rate																		129%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member]
Debt interest rate														8%			8%
Convertible debt principal amount																																			370,000
Maturity date																	Oct. 21, 2022
Debt instrument debt default interest rate									65%
Convertible debt principal amount																	$ 63,750																		0
Settled debt premium									$ 262,500																										$ 199,230	$ 262,500
Ownership limitations																																			150%
Debt instrument description									The conversion price for the above 1800 Diagonal notes is equal to 65% (representing a 35% discount) of the market price of the common stock, which is based on the average of the lowest three trading prices of the common stock for the ten trading days immediately prior to the delivery of a notice of conversion of such note.
Penalty amount																																			$ 1,000
Debt outstanding principal percentage									22%
Debt issue costs																$ 3,750
Premium Issued																																			56,538
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | Minimum [Member]
Debt instrument debt default interest rate									110%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | Maximum [Member]
Debt instrument debt default interest rate									129%
Ownership limitations									9.99%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | October Twenty One Two Thousand Twenty One [Member]
Debt issue costs																	$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | November Twenty Six Two Thousand Twenty One [Member]
Debt interest rate																8%
Maturity date																Nov. 26, 2022
Convertible debt principal amount																$ 53,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | January Four Two Thousand Twenty Two [Member]
Maturity date														Jan. 04, 2023
Convertible debt principal amount														$ 63,750
Debt issue costs														$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | March Seven Two Thousand Twenty Two [Member]
Debt interest rate													8%
Maturity date													Mar. 07, 2023
Convertible debt principal amount													$ 68,750
Debt issue costs													$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | April Twelve Two Thousand And Twenty Two [Member]
Debt interest rate											8%
Maturity date											Apr. 12, 2023
Convertible debt principal amount											$ 68,750
Debt issue costs											$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | May Twelve Twenty Twenty Two Thousand Eight hundred Diagonal Note [Member]
Debt interest rate										8%
Maturity date										May 12, 2023
Convertible debt principal amount										$ 63,750
Debt issue costs										$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | June Thirty Twenty Twenty Two Thousand Eight hundred Diagonal Note [Member]
Debt interest rate									8%																											8%
Maturity date									Jun. 30, 2023
Convertible debt principal amount									$ 105,000																											$ 105,000
Debt issue costs									3,750
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member]
Debt interest rate	10%
Convertible debt principal amount																																			338,700	54,300
Maturity date	Feb. 14, 2024
Convertible debt principal amount	$ 111,111								235,700						$ 170,000																				118,111	235,700
Interest payable current and non current									9,519																										4,726	9,519
Legal fees and due diligence expenses	$ 5,500
Settled debt premium									29,238																										182,376	29,238
Debt outstanding principal percentage	24%
Premium Issued																																			133,305
Debt issuance discount	$ 11,111
Debt principal increase percentage	20%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate	120%
Penalty amount	$ 250
Debt instrument debt default interest rate	60%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate	135%
Penalty amount	$ 500
Debt instrument debt default interest rate	65%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | December Seven Two Thousand Twenty One Geneva Roth [Member]
Debt interest rate															10%
Maturity date															Dec. 07, 2022
Original issue discounts amount															$ 25,500
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | March Twenty Nine Two Thousand Twenty Two [Member]
Debt interest rate												10%
Maturity date												Mar. 29, 2023
Convertible debt principal amount												$ 120,000
Original issue discounts amount												$ 18,000
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | August Fifteen Two Thousand Twenty Two [Member]
Debt interest rate							10%
Maturity date							Aug. 15, 2023
Convertible debt principal amount							$ 110,000
Legal fees and due diligence expenses							5,500
Debt issuance discount							$ 10,000
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Debt interest rate					8%	8%		8%
Lowest trading price percentage					65%			65%
Maturity date					Mar. 21, 2024			Aug. 12, 2023
Debt instrument debt default interest rate					24%
Convertible debt principal amount					$ 71,500	$ 71,500		$ 93,000																											75,300
Interest payable current and non current									4,263																											4,263
Legal fees and due diligence expenses					$ 2,500			$ 3,000
Ownership limitations					4.99%			4.99%
Original issue discount					$ 4,000	$ 4,000		$ 5,000
Penalty amount					250
Debt principal increase percentage						20%
Net proceeds					$ 65,000			$ 85,000
Conversion price, description					Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share.			The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price becomes $1.30 per share.
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate					110%
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate						125%
Penalty amount					$ 500
Securities Purchase Agreement [Member] | Red Road Holdings Securities Purchase Agreement [Member]
Debt interest rate				8%
Debt instrument debt default interest rate				22%
Convertible debt principal amount				$ 53,750
Interest payable current and non current																																			2,150
Legal fees and due diligence expenses				3,750
Proceeds from convertible debt				50,000
Settled debt premium				$ 28,942
Debt instrument description				65%
Penalty amount				$ 1,000
Percentage of outstanding shares of common stock				4.99%
Note prepayment pemium description				The Red Road Note may be prepaid until 180 days from its issuance date, subject to the following: if prepaid within 60 days of the issuance date, the prepayment premium is 110% of the face amount of such note plus any accrued interest, if prepaid after 60 days but less than 91 days from the issuance date, then the prepayment premium is 115% of the face amount plus any accrued interest of such note., if prepaid after 90 days but less than 121 days from the issuance date, then the prepayment premium is 120% of the face amount plus any accrued interest of such note, if prepaid after 120 days but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest of such note, and if prepaid after 150 days but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest of such note.
Amount of convertible debt outstanding with penalty																																			0
Amount repaid for covertible debt																																			53,750
Additional debt issued																																			28,942
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Debt interest rate		10%	10%
Convertible debt principal amount		$ 125,000
Convertible debt principal amount		125,000	$ 125,000
Interest payable current and non current																																			22,749
Proceeds from convertible debt		100,000
Original issue discount		25,000	25,000
Amount of convertible debt outstanding with penalty																																			144,951
Amount repaid for covertible debt																																			5,049
Additional debt issued																																			561
Debt instrument guaranteed interest		$ 12,500	$ 12,500
Number of shares issued		75,000	75,000
Amortization of debt discount		$ 37,500	$ 37,500
Debt Default penalty																																			25,000
Settlement of convertible debt																																			142,908
Auctus Financing Agreement [Member]
Convertible debt principal amount									0																											0	32,848	358,965
Crown Bridge Financing Agreement [Member] | Crown Bridge Partners, LLC [Member]
Convertible debt principal amount																																			$ 0
GW Holdings Financing Agreement [Member] | December Ten Two Thousand Twenty [Member]
Convertible debt principal amount																																						$ 90,000
Interest payable current and non current									7,885																											7,885
Settled debt premium									60,000																											60,000
Penalty amount																																				4,000
GW Holdings Financing Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member]
Settled debt premium																																					27,333
GW Holdings Financing Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member]
Convertible debt principal amount																						$ 90,000	90,000														41,000
Interest payable current and non current									0													$ 1,084	$ 1,084													0	4,636
Geneva Roth Financing Agreement [Member] | September 22, 2021 Geneva Roth [Member]
Convertible debt principal amount									299,500																											299,500	78,000
Interest payable current and non current									11,980																											11,980
Geneva Roth Financing Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member]
Convertible debt principal amount									0																											0	132,000
Interest payable current and non current																																					3,477
Settled debt premium									161,269																											161,269	$ 42,000
6th Street Financing Agreement [Member] | 1800 Diagonal Lending [Member]
Convertible debt principal amount																																				117,500
Convertible debt principal amount									265,000																											265,000
Interest payable current and non current									6,081																											6,081
Settled debt premium									$ 63,269																											$ 63,269

SCHEDULE OF INCOME TAX PROVISIO

SCHEDULE OF INCOME TAX PROVISION (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income tax (expense) benefit	$ (129,841)	$ (54,977)
UNITED STATES
Loss before Income taxes	(2,790,407)	(2,658,087)
Taxes under statutory US tax rates	(585,986)	(558,198)
Increase (decrease) in valuation allowance	861,178	339,334
Prior period adjustment	(218,947)
Foreign tax rate differential	(60,316)	(64,349)
Income tax rate change		272,008
Other	4,071	11,205
Income tax (expense) benefit

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Warrant Derivative Liability	$ 7,403	$ 7,403
Accrued Expenses	478,273	363,873
Prepaid Investor Services	575,021	427,318
Non-cash interest	758,797	709,936
Intangibles (Intellectual Property and Patent Cost)	321,557	293,260
Deferred Rent	4,550	4,198
Formation Expense	6,553	6,553
Net Operating Loss carryforward	8,910,873	8,759,357
Foreign Exchange Loss (OCI)	(39,379)	(39,379)
Revalue of derivative liability	572,141	460,772
Stock Based Compensation	84,028	84,028
Total Deferred tax assets	11,679,818	11,077,318
Research and Development	(202,568)	(170,435)
Gain on extinguishment of debt	47,393	(259,470)
Capital Raising Costs	(369,033)	(352,981)
Total deferred tax liabilities	(524,208)	(782,886)
Net deferred tax assets	11,155,610	10,294,432
Valuation allowance	(11,155,610)	(10,294,432)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)		12 Months Ended
	Mar. 27, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit		$ 129,841	$ 54,977
Operating loss carryforwards		$ 10,400,000
Income tax rate		25%	25%	26%
Tax benefit		$ (129,841)	$ (54,977)
Unrecognized tax benefits		0	0
Changes in unrecognized tax benefits		0	0
UNITED STATES
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit
Operating loss carryforwards		10,369,271
Tax benefit
AUSTRALIA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit		0	0
Operating loss carryforwards		26,933,305
Tax benefit		0	$ 0
AUSTRALIA | Expire In Two Thousand Twenty Four [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating loss carryforwards		7,300,000
AUSTRALIA | Not Expire [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating loss carryforwards		$ 3,100,000
Cares Act [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Income Tax Examination, Description	The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021.

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance	0.059	0.059
Weighted Average Price Per Share, Outstanding, Beginning balance	$ 4,533,000	$ 13,730,000
Number of Shares, Issued
Weighted Average Price Per Share, Issued
Number of Shares, Exercised
Weighted Average Price Per Share, Exercised
Number of Shares, Expired
Weighted Average Price Per Share, Expired
Number of Shares, Outstanding, Ending balance	0.059	0.059
Weighted Average Price Per Share, Outstanding, Ending balance	$ 4,533,000	$ 4,533,000
Number of Shares, Exercisable, Ending balance	0.059
Weighted Average Price Per Share, Exercisable, Ending balance	$ 4,533,000
Weighted average remaining contractual term	5 years 10 months 17 days
Weighted average fair value of options granted during the period	0 years
Aggregate intrinsic value

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023		Jun. 30, 2022
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance	105		121
Weighted Average Price Per Share, Outstanding, Ending balance	$ 200,270		$ 179,630
Number of Shares, Issued	3,305
Weighted Average Price Per Share, Issued	$ 10
Number of Shares, Exercised	(13)		(16)
Weighted Average Price Per Share, Exercised	$ 52,081		$ 42,860
Number of Shares, Forfeited	(1)
Weighted Average Price Per Share, Forfeited	$ 2,000,000
Number of Shares, Expired
Weighted Average Price Per Share, Expired
Number of Shares, Outstanding, Ending balance	3,396	[1]	105
Weighted Average Price Per Share, Outstanding, Ending balance	$ 5,440		$ 200,270
Number of Shares, Exercisable, Ending balance	3,379
Weighted Average Price Per Share, Exercisable, Ending balance	$ 5,467
Weighted average remaining contractual term	2 years 1 month 20 days
Aggregate intrinsic value
[1]The total warrants of 3,396

SCHEDULE OF WARRANT ACTIVITY (P

SCHEDULE OF WARRANT ACTIVITY (Parenthetical) (Details) - shares	Jun. 30, 2023		Jun. 30, 2022
Equity [Abstract]
Number of Shares, Outstanding, Ending balance	3,396	[1]	105
[1]The total warrants of 3,396

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Jun. 30, 2023		Jun. 30, 2022	Jun. 30, 2021
Class of Stock [Line Items]
Number of warrants	3,396	[1]	105	121
Exercisable	3,379
Series A Warrants [Member]
Class of Stock [Line Items]
Number of warrants	10
Exercisable	10
Series B Warrants [Member]
Class of Stock [Line Items]
Number of warrants	17
Exercisable	17
Series C Warrants [Member]
Class of Stock [Line Items]
Number of warrants	64
Exercisable	47
Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of warrants	3,305
Exercisable	3,305
[1]The total warrants of 3,396

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)																						1 Months Ended		3 Months Ended		12 Months Ended
	Jul. 10, 2023 shares	Mar. 08, 2023 USD ($) shares	Nov. 16, 2022 $ / shares shares	Nov. 16, 2022 USD ($) $ / shares shares	Nov. 03, 2022 USD ($) shares	Nov. 03, 2022 USD ($) shares	Oct. 25, 2022 USD ($) $ / shares shares	Aug. 16, 2022 USD ($) $ / shares shares	Jul. 13, 2022 USD ($) $ / shares shares	Jul. 02, 2022 shares	Jun. 30, 2022 USD ($) $ / shares shares	Apr. 13, 2022 USD ($) $ / shares shares	Feb. 17, 2022 USD ($) $ / shares shares	Jan. 24, 2022 USD ($) $ / shares shares	Jan. 20, 2022 USD ($) $ / shares shares	Nov. 30, 2021 USD ($) $ / shares shares	Aug. 12, 2021 USD ($) $ / shares shares	Jul. 20, 2021 USD ($) $ / shares shares	Sep. 24, 2020	Apr. 03, 2020 $ / shares shares	Mar. 20, 2020 Integer $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	May 31, 2019 USD ($) $ / shares shares	Sep. 18, 2023 USD ($) shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jul. 31, 2023 shares	Jul. 01, 2023 $ / shares	Jun. 30, 2023 AUD ($) shares	Mar. 31, 2023 shares	Sep. 21, 2022 shares	Sep. 20, 2022 shares	Aug. 31, 2022 USD ($)	Jul. 12, 2022 shares	Jun. 30, 2022 AUD ($) shares	May 18, 2022 shares	May 17, 2022 shares	Aug. 12, 2021 AUD ($)
Class of Stock [Line Items]
Common Stock, Shares Authorized | shares											10,000,000,000														10,000,000,000	10,000,000,000	10,000,000,000				10,000,000,000		10,000,000,000	3,000,000,000			10,000,000,000	3,000,000,000	1,000,000,000
Number of preferred stock authorized shares | shares																																	1,500,005					1,500,005
Preferred stock, shares authorized | shares											1,500,005														1,500,005	1,500,005	1,500,005				1,500,005		10,001,500,005				1,500,005	3,001,500,005
Stockholders equity reverse stock split																			one-for-one thousand (1:1,000)
Preferred stock, par value | $ / shares											$ 0.01														$ 0.01	$ 0.01	$ 0.01
Stock issued during period, value																										$ 48,469	$ 99,285
Common stock value											$ 220														$ 220	6,031	220
Proceeds from issuance of common stock									$ 24,711																99,285	24,711	99,285
Subscription receivable											23,758														23,758		23,758								$ (23,758)
Subscription receivable											$ (23,758)														$ (23,758)		$ (23,758)								$ 23,758
Subscription receivable value																										$ 23,758
Warrants exercised | shares											220,351														220,351	6,031,250	220,351				6,031,250						220,351
Debt instrument face amount											$ 1,000														$ 1,000	$ 168,200	$ 1,000
Accrued interest											8,000														8,000	16,632	8,000
Conversion fees																										1,838
Debt instrument fair value											28,572														28,572		28,572
Loss on extinguishment debt conversion											19,572														19,572	369,602	19,572
Loss on extinguishment debt conversion											2,069														2,069	352,051	2,069
Premiums to additional paid in capital																										411,111	335,677
Gain (loss) on extinguishment of debt																										(2,660,566)	(2,658,087)
Stock issued during period value services																										138,948
Share based compensation																										$ 2,408	72,513
Share price | $ / shares																										$ 0.135
Accrued salaries current											$ 56,050														$ 56,050	$ 64,627	56,050				$ 96,000						$ 82,500
Deemed dividend																										466,273	700,340
Debt discount to be amortized																										$ 202,952	$ 47,971
Restricted stock units, value | $ / shares
Share based compensation																										$ 0	$ 72,513
Unvested stock option expense																										$ 0
Stock options granted | shares																										0	0
Warrants exercisable | shares																										13	16
Issuance of common stock for exercise of warrants | shares		4
Warrants aggregate price																										$ 475,000	$ 625,001
Share issued value																											$ 448,440
Common stock per share | $ / shares											$ 0.001														$ 0.001	$ 0.001	$ 0.001
Gains losses on extinguishment of debt																										$ 25,969	$ (17,503)
Proceeds from warrants exercise																										$ 475,000	625,001
2019 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares																										234					234
Series B Warrant [Member]
Class of Stock [Line Items]
Offer from Series B warrants																										$ 475,000	$ 625,000
Warrants exercised | shares											16														16	12	16				12						16
Warrant exercise price | $ / shares											$ 40,000														$ 40,000	$ 40,000	$ 40,000
Series A And C Warrant [Member]
Class of Stock [Line Items]
Stock issued during period | shares																											56,800
Series A Warrants [Member]
Class of Stock [Line Items]
Stock issued during period | shares																										559,999
Warrants exercised | shares																										559,999					559,999
Warrants exercised | shares											56,800														56,800	0.97	56,800				0.97						56,800
Warrant exercise price | $ / shares											$ 0.284														$ 0.284	$ 0.97	$ 0.284
Warrants exercise price | $ / shares											200,000														200,000	200,000	200,000
Alternate cashless warrant exercise price | $ / shares											$ 0.001														$ 0.001	$ 0.001	$ 0.001
Percentage of exercise price and market price																										70%
Series B Warrants [Member]
Class of Stock [Line Items]
Shares issued | shares		3
Warrants exercised | shares											16														16	12	16				12						16
Share issued value		$ 100,000
Proceeds from warrants exercise																										$ 475,000	$ 625,001
Mr. Nathanielsz [Member]
Class of Stock [Line Items]
Share based compensation																											8,299
Adjustments to additional paid in capital stock issued issuance costs																											177,840
Chief Executive Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares																							0.078
Chief Scientific Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares																							0.039
Legal Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares															$ 30
Stock issued during period shares for services | shares															667
Stock issued during period value services															$ 20,000
Share based compensation																											20,000
Consultant Services [Member] | Consultant [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares														$ 20
Stock issued during period shares for services | shares														2,274
Stock issued during period value services														$ 45,030
Share based compensation																											45,030
Consultant Services [Member] | Consultant One [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares													$ 20
Stock issued during period shares for services | shares													1,148
Stock issued during period value services													$ 24,000
Share based compensation																											24,000
Consultant Services [Member] | Consultant Two [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares												$ 12.2
Stock issued during period shares for services | shares												3,834
Stock issued during period value services												$ 46,771
Share based compensation																											$ 46,771
Consultant Services [Member] | Consultant Three [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares											$ 3.70														$ 3.70	$ 0.135	$ 3.70
Stock issued during period shares for services | shares											12,271															608,423
Stock issued during period value services											$ 45,403															$ 82,137
Share based compensation																										82,137	$ 45,403
Stock issued during period shares employee benefit plan | shares										12,271
Gain Loss On Extinguishment of Debt [Member]
Class of Stock [Line Items]
Gain (loss) on extinguishment of debt																										$ 17,551
Subsequent Event [Member]
Class of Stock [Line Items]
Stock issued during period | shares																								4,898,307
Average contractual conversion prices | $ / shares																														$ 0.02
Debt instrument face amount																								$ 98,954
Accrued interest																								7,071
Conversion fees																								$ 1,277
Subsequent Event [Member] | Consultant Services [Member] | Consultant Three [Member]
Class of Stock [Line Items]
Stock issued during period shares employee benefit plan | shares	608,423
Convertible Debt [Member]
Class of Stock [Line Items]
Stock issued during period | shares																										5,061,180	96,960
Proceeds from issuance of common stock																										$ 1,387,723	$ 657,125
Warrants exercised | shares											7,326														7,326	807,230	7,326				807,230					7,326	7,326
Average contractual conversion prices | $ / shares																										$ 0.17
Debt instrument face amount											$ 599,148														$ 599,148	$ 935,699	$ 599,148
Accrued interest											36,154														36,154	80,586	36,154
Conversion fees											$ 2,250														$ 2,250	1,838	2,250
Proceeds from issuance of shares under stock options																										19,572	$ 19,572
Debt instrument fair value																										$ 556,272
Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term																											3 days
Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility											1.28														1.28	5.24	1.28				5.24						1.28
Convertible Debt [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility											228														228	334.56	228				334.56						228
Convertible Debt [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Warrants exercised | shares																													807,230
Common Stock [Member]
Class of Stock [Line Items]
Stock issued during period, value																										$ 14	$ 26
Shares issued price per share | $ / shares									$ 2		$ 10														$ 10		$ 10
Stock issued during period | shares									14,337																25,663	14,337	25,663
Warrants exercised | shares											16														16		16										16
Gain (loss) on extinguishment of debt
Stock issued during period shares for services | shares																										79,412
Stock issued during period value services																										$ 79
Issuance of common stock for exercise of warrants | shares		4																								12	16
Warrants aggregate price
Common Stock [Member] | Series A Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares																										206,000					206,000
Common Stock [Member] | Series B Warrants [Member]
Class of Stock [Line Items]
Stock issued during period, value																										$ 40,000
Stock issued during period | shares																										12	16
Common Stock [Member] | Consultant [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares			$ 0.07	$ 0.07			$ 0.90
Stock issued during period shares for services | shares			73,301	73,301			6,111
Stock issued during period value services				$ 51,311			$ 5,500
Share based compensation																										$ 51,311
Common Stock [Member] | Legal Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares																	$ 50
Stock issued during period shares for services | shares																	167
Stock issued during period value services																	$ 7,883
Share based compensation																											$ 7,883
Common Stock [Member] | Consultant Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares																						$ 40
Stock issued during period shares for services | shares																						2,820
Stock issued during period value services																						$ 104,611
Share based compensation																											104,611
Stock issued during period shares employee benefit plan | shares													1,148,326
Common Stock [Member] | Bonus Payable [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares																	$ 30
Stock issued during period shares for services | shares																	2,800
Bonus payable											$ 84,000														$ 84,000		84,000	$ 84,000
Stock issued during period value services																	$ 87,920
Share based compensation																											3,920
Series B Warrants [Member]
Class of Stock [Line Items]
Offer from Series B warrants		$ 250
Warrant [Member]
Class of Stock [Line Items]
Warrants exercised | shares								1,000
Deemed dividend																										142,575
Warrants aggregate price		$ 150,000
Common stock per share | $ / shares								$ 10
Warrants expiration date								Aug. 16, 2025
Fair market value of warrants								$ 2,408
Stock valuation price per share | $ / shares								$ 2.60
Warrant exercise price | $ / shares								$ 10
Share based compensation expenses																										2,408
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Volatility								0
Warrant [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term								3 years
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility								3.19
Warrant [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility								236
Warrant [Member] | Affiliated Entity [Member]
Class of Stock [Line Items]
Warrants exercised | shares								2,305
Common stock per share | $ / shares								$ 10
Fair market value of warrants								$ 5,551
Stock valuation price per share | $ / shares								$ 2.60
Warrant exercise price | $ / shares								$ 10
Warrants outstanding payable								$ 23,050
Gains losses on extinguishment of debt																										17,499
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Volatility								0
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term								3 years
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility								3.19
Warrant [Member] | Affiliated Entity [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility								236
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares																							0.117
Restricted stock units, value | $ / shares																							$ 4,250,000
Fair value granted, shares																							$ 497,240
Unrecognized restricted stock units expense																										248,620	248,620
Restricted stock units not yet vested, shares											$ 248,620														$ 248,620	$ 248,620	$ 248,620
Unvested Restricted Stock Units [Member]
Class of Stock [Line Items]
Unvested restricted stock units | shares											0.06														0.06	0.06	0.06				0.06						0.06
Maximum [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Average contractual conversion prices | $ / shares											$ 40														$ 40		$ 40
Maximum [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term																										8 months 23 days
Minimum [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Average contractual conversion prices | $ / shares											$ 10														$ 10		$ 10
Minimum [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term																										3 days
Common Stock Purchase Agreement [Member] | Dutchess [Member]
Class of Stock [Line Items]
Agreement term						36 months										36 months
Percentage of lowest trading price equals purchase price of each shares																92%
Percentage of average daily trading volume					200%											300%
Common stock value					$ 250,000	$ 250,000										$ 250,000
Deferred offering cost																20,000
Beneficial ownership limitation, percentage					9.99%	9.99%
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Common stock value																$ 20,000
Restricted stock units, shares | shares																1,000
Shares issued price per share | $ / shares																$ 20
Deferred offering cost											$ 20,000														$ 20,000		$ 20,000
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock issued during period, value						$ 5,000,000										$ 5,000,000
Underlying Financing Agreements [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares																										3,764,903,510					3,764,903,510
Nathanielsz Cancellation Agreement [Member] | Mr. Nathanielsz [Member]
Class of Stock [Line Items]
Common stock value																		$ 186,139
Percentage of bonus of annual base salary																	200%	78%
Officers compensation																		$ 177,840
Debt conversion converted instrument shares issued | shares																		5,928
Share price | $ / shares																		$ 30
Cancellation Agreement [Member] | Dr. Kenyon [Member]
Class of Stock [Line Items]
Share based compensation																											4,788
Accrued salaries current																	$ 102,600
Cancellation Agreement [Member] | Dr. Kenyon [Member]
Class of Stock [Line Items]
Common stock value																	$ 107,388
Shares issued price per share | $ / shares																	$ 30
Stock issued during period shares employee benefit plan | shares																	3,420
Adjustments to additional paid in capital stock issued issuance costs																											102,600
Director Agreement [Member] | Josef Zelinger [Member]
Class of Stock [Line Items]
Common stock value																												$ 87,920
Stock issued during period | shares																												2,800
Share based compensation																											3,920
Share price | $ / shares																												$ 30
Adjustments to additional paid in capital stock issued issuance costs																											84,000
Accrued salaries current																	$ 184																							$ 250
Accrued liabilities																												$ 84,000
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Accrued interest																										$ 22,749
Debt discount to be amortized																										210,278	$ 73,500
Equity purchase agreement description																				the Company closed on a transaction related to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into on March 30, 2020, whereby an investor purchased from the Company, 7.5 units, each consisting of (i) 1.5 shares of the Company’s common stock, or pre-funded warrants upon Investor’s election due to the 4.99% blocker provision and (ii) 1.5 warrants to purchase one share of Common Stock (“Series A Warrants”, and collectively with the Common Stock the “Units”).
Securities Purchase Agreement [Member] | Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares																				10
Warrant exercise price | $ / shares																				$ 100
Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Shares issued | shares					75,000	75,000
Debt instrument face amount					$ 125,000	$ 125,000
Accrued interest																										$ 22,749
Debt discount to be amortized					$ 37,500	$ 37,500
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares											500,000														500,000	500,000	500,000				500,000						500,000
Preferred stock, par value | $ / shares											$ 0.01														$ 0.01	$ 0.01	$ 0.01
Preferred stock shares outstanding | shares											500,000														500,000	0	500,000				0	0					500,000
Preferred stock shares issued | shares											500,000														500,000	0	500,000				0						500,000
Shares issued | shares											0														0	0	0				0						0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares											5														5	5	5				5						5
Preferred stock, par value | $ / shares											$ 0.01														$ 0.01	$ 0.01	$ 0.01
Preferred stock shares outstanding | shares											1														1	1	1				1						1
Preferred stock shares issued | shares											1														1	1	1				1						1
Shares issued | shares											0														0	0	0				0						0
Series A Warrant [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares																										$ 200,000
Series B Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants exercised | shares																				64	4
Warrant exercise price | $ / shares																					$ 40,000
Warrants term																					3 years
Series B Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares																					64
Warrants exercisable | shares																					38
Trading days | Integer																					10
Series B Warrants [Member] | Securities Purchase Agreement [Member] | Holder [Member]
Class of Stock [Line Items]
Stock issued during period | shares																					4
Series C Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants exercised | shares																				64
Series C Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares																					64
Warrant exercise price | $ / shares																					$ 200,000
Warrants term																					3 years
Series A Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares																					11
Warrant exercise price | $ / shares																					$ 200,000
Warrants term																					3 years
Warrant description																					the Series A Warrants contain a provision for a cashless conversion at the Holder’s option should the trading price of the Common Stock fall below $200,000, per share calculated based on the difference between the exercise price of the Series A Warrant and 70% of the Market Price, as defined therein (the” Alternate Cashless Exercise”). The Alternate Cashless Exercise price is $0.001.

SCHEDULE OF RIGHT OF USE ASSET

SCHEDULE OF RIGHT OF USE ASSET (Details) - Related Party [Member] - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Less: accumulated amortization	(27,213)	(3,678)
Right-of-use asset, net	$ 38,988	$ 62,523

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - Related Party [Member] - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Office lease	$ 66,201	$ 66,201
Reduction of lease liability	(25,418)	(3,277)
Less: office lease, current portion	(21,505)	(20,605)
Long term portion of lease liability	$ 19,278	$ 42,319

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2024	$ 23,990
Fiscal Year 2025	19,992
Imputed interest	(3,199)
Total operating lease liability	$ 40,783

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

1 Months Ended

12 Months Ended

Nov. 16, 2022 shares

Nov. 16, 2022 shares

Oct. 25, 2022 shares

Jul. 27, 2022 USD ($)

Jul. 27, 2022 EUR (€)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

May 04, 2022 USD ($)

Feb. 17, 2022 shares

Jan. 24, 2022 shares

Oct. 02, 2021 USD ($)

Oct. 01, 2020 USD ($)

Oct. 01, 2020 EUR (€)

Sep. 13, 2018 USD ($)

Sep. 13, 2018 EUR (€)

Jul. 31, 2023 USD ($)

Jul. 31, 2023 EUR (€)

Mar. 31, 2023 USD ($)

Mar. 31, 2023 EUR (€)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Sep. 30, 2022 USD ($)

Sep. 30, 2022 EUR (€)

Aug. 31, 2022 USD ($)

Aug. 31, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Sep. 30, 2021 shares

Mar. 31, 2021 USD ($)

Mar. 31, 2021 EUR (€)

Nov. 30, 2020 EUR (€)

Jun. 30, 2012

Jun. 30, 2023 USD ($) shares

Jun. 30, 2022 USD ($)

Jun. 30, 2021

Total litigation penalty amount

$ 30,000

[custom:RoyaltiesPercentage]

2%

2%

unreimbursed lab fees

18,056

$ 14,364

Royalty fees

0

0

Accrued expense

16,632

8,000

Payments for Rent

$ 28,841

$ 28,366

Incremental borrowing rate

8%

Weighted average remaining lease term

1 year 9 months 7 days

Accounting Standards Update 2016-02 [Member]

Operating lease right of use asset

$ 66,201

$ 66,201

Operating lease liabilities

$ 66,201

$ 66,201

Common Stock [Member]

Stock issued during period shares for services | shares

79,412

Common Stock [Member] | Consultant [Member]

Stock issued during period shares for services | shares

73,301

73,301

6,111

Consultant Services [Member] | Consultant [Member]

Stock issued during period shares for services | shares

2,274

Consultant Services [Member] | Common Stock [Member]

Stock issued during period shares employee benefit plan | shares

1,148,326

Stock issued during period shares for services | shares

2,820

University of Jaen [Member]

Payment for services

$ 30,268

€ 25,837

Royalty Agreement Terms [Member]

Operating leases income statement revenue percentage

2%

License Agreement Terms [Member]

Operating leases income statement revenue percentage

5%

1-Year Collaboration Agreement [Member]

Payment for services

$ 59,508

€ 52,000

2-Year Collaboration Agreement [Member]

Payment for services

$ 35,145

€ 30,000

$ 45,775

€ 40,000

Royalty percentage

2%

Research Agreement [Member] | Two Members of Scientific Advisory Board [Member]

Payment of royalties percentage of net revenues

1%

1%

Research Agreement [Member] | University of Jaen [Member]

Payment for services

$ 53,806

€ 53,200

Consulting Agreement [Member]

Payment for consulting

$ 7,000

Monthly Fee

$ 50,000

Stock fee percentage

9.90%

Accrued expense

$ 608,423

Other liabilities

0

New Three-Year Operating Lease Agreement [Member]

Lessee operating lease term

3 years

3 years

Payments for Rent

$ 2,176

$ 3,000

From 2012 through the 2014 [Member]

Total litigation penalty amount

$ 10,000

Installment 1 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services | €

€ 5,000

Installment 1 [Member] | Research Agreement [Member]

Payment for services

$ 18,407

€ 18,200

Installment 2 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 5,858

€ 5,000

Installment 2 [Member] | Research Agreement [Member]

Payment for services

$ 8,091

€ 8,000

Installment 3 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 3 [Member] | Research Agreement [Member]

Payment for services

$ 7,080

€ 7,000

Installment 4 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 4 [Member] | Research Agreement [Member]

Payment for services

$ 10,114

€ 10,000

Installment 5 [Member] | Research Agreement [Member] | Forecast [Member]

Payment for services

$ 10,114

€ 10,000

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details Narrative)																				1 Months Ended	12 Months Ended
	Oct. 26, 2022 USD ($)	Oct. 26, 2022 AUD ($)	Aug. 01, 2022 USD ($)	Aug. 01, 2022 AUD ($)	May 04, 2022 USD ($)	May 04, 2022 AUD ($)	Aug. 12, 2021 USD ($) shares	May 14, 2019 USD ($) $ / shares shares	May 14, 2019 AUD ($) shares	Mar. 16, 2018 USD ($)	Mar. 16, 2018 AUD ($)	Feb. 01, 2018 USD ($)	Feb. 01, 2018 AUD ($)	May 05, 2016 USD ($)	May 05, 2016 AUD ($)	Feb. 25, 2016 USD ($)	Feb. 25, 2016 AUD ($)	Feb. 25, 2015 USD ($)	Feb. 25, 2015 AUD ($)	May 31, 2019 shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2023 AUD ($) shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 AUD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2021 AUD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)	May 05, 2016 AUD ($)
Related Party Transaction [Line Items]
Payments for Rent | $																					$ 28,841		$ 28,366
Bonus payable																					$ 48,905	$ 73,387	$ 99,691	$ 144,166
Exercise price | $ / shares
Granted exercise price | $ / shares
Accrued salaries																					$ 64,627		$ 56,050				$ 96,000	$ 82,500
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments form related party | $																										$ 221,890
Bonus payable																									$ 166,418	$ 422,610
Remaining bonus amount																					$ 71,929	$ 107,937	$ 125,386	$ 181,324
Restricted stock shares of common stock																				0.078
Nathanielsz Employment Agreement [Member]
Related Party Transaction [Line Items]
Expired date																		Feb. 25, 2019	Feb. 25, 2019
Base salary per month | $																			$ 25,000
Annual salary	$ 414,900	$ 600,000																$ 205,680	$ 300,000
Percentage of pension of monthly salary																					9.50%	9.50%
Percentage of bonus of annual base salary																					200%	200%
Nathanielsz Employment Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Annual salary			$ 414,900	$ 600,000						$ 274,240	$ 400,000
Percentage of bonus of annual base salary																		200%	200%		100%	100%
Nathanielsz Employment Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Annual salary			309,313	400,000						$ 205,680	$ 300,000
Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Bonus payable | $																									$ 316,957
Employment Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																					0.04	0.04
Employment Agreement [Member] | Initial Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock								0.04	0.04														0.04	0.04
Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock unit issuable																					0.04	0.04
Services Agreement [Member]
Related Party Transaction [Line Items]
Number of restricted stock unit vested, shares																					0.02	0.02
Restricted stock unit issuable																							0.02	0.02
Services Agreement [Member] | Initial Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock								0.02	0.02
Services Agreement [Member] | Additional Kenyon RSUs [Member]
Related Party Transaction [Line Items]
Restricted stock shares of common stock								0.02	0.02
Accounting Standards Update 2016-02 [Member]
Related Party Transaction [Line Items]
Operating lease, description														Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022.	Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022.
North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Lessee, operating lease, term of contract														5 years															5 years
Operating leases rent expense, minimum rentals														$ 28,325	$ 39,600
Goods and service tax														2,575	$ 3,600
Payments for Rent																					$ 105,377	$ 158,129	$ 84,452	$ 122,129
North Horizon Pty Ltd [Member] | Three Year Operating Lease Agreement [Member]
Related Party Transaction [Line Items]
Lessee, operating lease, term of contract					3 years	3 years
Payments for Rent					$ 2,176	$ 3,000
Former Director [Member]
Related Party Transaction [Line Items]
Loans from related party | $																					29,630		30,746
Due to related parties | $																					$ 49,314		51,171
Nathanielsz [Member] | North Horizon Pty Ltd [Member]
Related Party Transaction [Line Items]
Operating leases, future minimum payments due														$ 141,629															$ 198,000
Mrs. Nathanielsz [Member]
Related Party Transaction [Line Items]
Annual salary												$ 80,904	$ 120,000
Payments form related party																							$ 5,577	$ 7,689
James Nathanielsz [Member]
Related Party Transaction [Line Items]
Payments form related party																$ 3,205	$ 4,481
Mr. Nathanielsz [Member] | Board of Directors [Member]
Related Party Transaction [Line Items]
Officers compensation			$ 96,810	$ 140,000			$ 177,840
Debt conversion, converted instrument, shares issued							5,928,000
Mr. Nathanielsz [Member] | Employment Agreement [Member]
Related Party Transaction [Line Items]
Annual salary								$ 309,313	$ 400,000
Agreement term								3 years	3 years
Option purchase shares								0.04	0.04
Exercise price | $ / shares								$ 4,675,000
Market price								110%	110%
Granted exercise price | $ / shares								$ 4,250,000
Option term								10 years	10 years
Dr. Kenyon [Member] | Services Agreement [Member]
Related Party Transaction [Line Items]
Annual salary								$ 41,580	$ 54,000
Agreement term								3 years	3 years
Option purchase shares								0.02	0.02
Exercise price | $ / shares								$ 4,250,000
Market price								100%	100%
Option term								10 years	10 years
Dr. Kenyon [Member] | Cancellation Agreement [Member]
Related Party Transaction [Line Items]
Debt conversion, converted instrument, shares issued							3,420
Cancellation of accrued salary | $							$ 102,600

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 79,111	$ 73,500
Proceeds from convertible debt	$ 590,250	$ 766,500
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	17%	21%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	32%	47%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	25%	32%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Four [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Five [Member]
Concentration Risk [Line Items]
Concentration risk percentage	18%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100%	100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 101,250	$ 160,000
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	189,000	360,000
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	150,000	246,500
Lender Four [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	50,000
Lender Five [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 100,000
Lenders [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt		$ 766,500

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) - Convertible Debt [Member]	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Measurement Input, Price Volatility [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	334.56	228
Measurement Input, Price Volatility [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	228.29
Measurement Input, Price Volatility [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	256.02
Measurement Input, Expected Term [Member]
Derivative [Line Items]
Debt instrument, measurement input, term		3 days
Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	3 days
Measurement Input, Expected Term [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	2 months 19 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	8 months 23 days
Measurement Input, Expected Term [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	3 months 10 days
Measurement Input, Risk Free Interest Rate [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	5.24	1.28
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	3.13
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	4.42

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities	$ 423,209	$ 151,262
Total	423,209	151,262
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Embedded conversion option liabilities	423,209	151,262
Total	$ 423,209	$ 151,262

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 151,262
Gain on debt extinguishment	(25,969)	$ 17,503
Change in fair value included in statements of operations	530,330	99,111
Ending balance	423,209	151,262
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	151,262	54,220
Initial fair value of embedded conversion option derivative liability recorded as debt discount	93,668
Gain on debt extinguishment	(352,051)	(2,069)
Change in fair value included in statements of operations	530,330	99,111
Ending balance	$ 423,209	$ 151,262

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 0.135
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 75,300	$ 79,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)

3 Months Ended

12 Months Ended

Aug. 23, 2023 USD ($)

Aug. 16, 2023 USD ($)

Aug. 15, 2023 USD ($)

Jul. 20, 2023 USD ($) $ / shares

Jul. 19, 2023 USD ($)

Jul. 06, 2023 USD ($)

Jul. 05, 2023 USD ($) $ / shares shares

Sep. 21, 2022 USD ($)

Sep. 21, 2022 USD ($)

Aug. 12, 2022 USD ($)

Sep. 18, 2023 USD ($) shares

Jun. 30, 2023 USD ($) $ / shares shares

Jun. 30, 2022 USD ($) $ / shares

Jul. 05, 2023 AUD ($)

Jul. 01, 2023 $ / shares

Nov. 03, 2022 USD ($)

Aug. 16, 2022 $ / shares

Subsequent Event [Line Items]

Principal amount

$ 168,200

$ 1,000

Penalty amount

30,000

Debt instrument unamortized discount

$ 38,994

$ 31,669

Common stock, par value | $ / shares

$ 0.001

$ 0.001

Deemed dividend

$ 466,273

$ 700,340

Accrued interest

16,632

8,000

Conversion fees

1,838

Debt instrument unamortized premium

$ 91,171

313,127

Series A Warrant [Member]

Subsequent Event [Line Items]

Warrant, exercise price | $ / shares

$ 0.011

New issuance, shares | shares

2,282,000

Warrant [Member]

Subsequent Event [Line Items]

Common stock, par value | $ / shares

$ 10

Deemed dividend

$ 142,575

GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Accrued interest

2,945

Letter Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Settlement of convertible debt

$ 143,000

Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

18%

Debt instrument unamortized discount

$ 232,674

452,308

Accrued interest

22,749

Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Principal amount

$ 125,000

Debt instrument, interest rate, stated percentage

10%

Settlement of convertible debt

142,908

Debt instrument unamortized discount

$ 25,000

Accrued interest

22,749

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Principal amount

$ 71,500

$ 71,500

$ 93,000

$ 75,300

Debt instrument maturity date

Mar. 21, 2024

Aug. 12, 2023

Debt instrument, interest rate, stated percentage

8%

8%

8%

Debt instrument debt default interest rate

24%

Percentage of outstanding shares of common stock

4.99%

4.99%

Penalty amount

$ 250

Debt instrument unamortized discount

4,000

$ 4,000

$ 5,000

Legal fees

$ 2,500

$ 3,000

Conversion price, description

Such note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2 (the “September Fixed Price”). However, in the event the common stock trades below $1.40 per share for more than five consecutive trading days, then the September Fixed Price becomes $0.90 per share.

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital by surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of common stock at a price per share equal to $2.80 per share (the “Fixed Price”). However, in the event the common stock trades below $2 per share for more than five consecutive trading days, then the Fixed Price becomes $1.30 per share.

Debt instrument increase principal percentage

20%

Accrued interest

$ 4,263

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

125%

Penalty amount

$ 500

Subsequent Event [Member]

Subsequent Event [Line Items]

Principal amount

$ 98,954

Debt instrument increase interest rate

18%

New issuance, shares | shares

4,898,307

Debt instrument contractual conversion price | $ / shares

$ 0.02

Accrued interest

$ 7,071

Conversion fees

1,277

Debt instrument unamortized premium

$ 21,737

Subsequent Event [Member] | Loans Payable [Member]

Subsequent Event [Line Items]

Principal amount

$ 132,000

Debt instrument maturity date

Nov. 15, 2023

Debt instrument, interest rate, stated percentage

10%

Debt instrument, discount amount

$ 120,000

Debt instrument description

The Company has the right to prepay the principal and accrued but unpaid interest due under the Promissory Note, together with any other amounts that the Company may owe the August 2023 Lender under the terms of the Promissory Note, on or before September 14, 2023 at a 110% premium of the face amount plus accrued and unpaid interest and any other amounts owed to the August 2023 Lender, which increases to (i) 120% if prepaid after such date, but on or before October 14, 2023, and (ii) 130% if prepaid after October 14, 2023, unless the Company and the Lender agree to otherwise effect repayment.

Subsequent Event [Member] | Letter Agreement [Member]

Subsequent Event [Line Items]

Principal amount

$ 153,256

$ 230,000

Term of agreement

3 years

Debt instrument maturity date

Jul. 05, 2026

Debt instrument, interest rate, stated percentage

10%

10%

Issue of warrants | shares

15,000,000

Warrant, exercise price | $ / shares

$ 0.01

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member]

Subsequent Event [Line Items]

Debt instrument, interest rate, stated percentage

8%

Debt instrument description

The conversion price for the above notes shall be equal to a 35% discount of the market price which means the average of the lowest three trading prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion. Notwithstanding the foregoing, 1800 Diagonal shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by 1800 Diagonal and its affiliates, exceeds 9.99% of the outstanding shares of the Company’s common stock. The Company treats this convertible notes as stock settled debt under ASC 480.

Debt instrument debt default interest rate

35%

Percentage of outstanding shares of common stock

150%

Debt default amount percentage

22%

Penalty amount

$ 1,000

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

129%

Percentage of outstanding shares of common stock

9.99%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | July Six Twenty Twenty Three Thousand Eighthundred Diagonal Note [Member]

Subsequent Event [Line Items]

Principal amount

$ 65,000

Debt instrument maturity date

Jun. 29, 2024

Debt issuance costs

$ 5,000

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | July Nineteen Twenty Twenty Three Thousand Eighthundred Diagonal Note [Member]

Subsequent Event [Line Items]

Principal amount

$ 45,000

Debt instrument maturity date

Jul. 19, 2024

Debt issuance costs

$ 5,000

Subsequent Event [Member] | Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | August Sixteen Twenty Twenty Three Thousand Eighthundred Diagonal Note [Member]

Subsequent Event [Line Items]

Principal amount

$ 55,000

Debt instrument maturity date

Aug. 16, 2024

Debt issuance costs

$ 5,000

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]

Subsequent Event [Line Items]

Principal amount

$ 77,500

Debt instrument maturity date

Feb. 23, 2024

Debt instrument, interest rate, stated percentage

8%

Debt instrument debt default interest rate

24%

Debt instrument unamortized discount

$ 5,000

Legal fees

$ 2,500

Conversion price, description

The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. The initial conversion price for the GS Capital Note is equal to $0.04 per share (the “Fixed Price”), provided that the Fixed Price will be reduced to $0.02 per share in the event that the market price of the Common Stock trades below $0.03 per share for five consecutive trading days. In the event of a default under the Note and unless the Fixed Price is lower, such conversion price will equal the lowest trading price of the Common Stock for the ten trading days immediately preceding such default, which price is subject to re-adjustment every thirty calendar days during the period in which the Company remains in default. Pursuant to the Note, in the event that such conversion price is below the par value of the Common Stock, the Company has agreed to take all steps to reduce such par value or conduct a reverse split of its Common Stock, as applicable. Notwithstanding the foregoing, such conversion price and lookback periods are subject to adjustment in favor of the Investor in the event the Company issues securities to another party with more favorable conversion terms, and such conversions are subject to a 4.99% beneficial ownership limitation (which may be increased to 9.9% upon 60 days’ prior written notice from the holder of the Note) and adjustments for mergers, consolidations, reorganizations and similar events set forth in the Note, other than a transfer or sale of all or substantially all Company assets. Pursuant to the Note, the Company is required to maintain an initial reserve of at least 400% of the number of Conversion Shares, subject to any increase of such reserved amount to reflect the Company’s obligations under the Note.

Debt instrument increase principal percentage

20%

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

110%

Penalty amount

$ 250

Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]

Subsequent Event [Line Items]

Debt instrument debt default interest rate

125%

Penalty amount

$ 500

Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Investor [Member]

Subsequent Event [Line Items]

Agreement term

24 months

Drawdown description

pursuant to a Drawdown Notice cannot exceed the lesser of (i) 200% of the average daily traded value of the Common Stock during the five (5) business days immediately preceding a Drawdown Notice or (ii) $200,000; provided that in no event may a Drawdown Notice be for less than $5,000, exceed 52,500,000 Shares or cause the Investor’s ownership to exceed 4.99% of the outstanding number of shares of Common Stock immediately prior to the issuance of such Shares. The actual amount of proceeds that the Company will receive in connection with each Drawdown Notice is determined under the Equity Line Agreement by multiplying the number of Shares to be sold by the applicable purchase price per share, which is equal to 85% of the lowest traded price of the Common Stock during the 7 business days immediately following the Clearing Date, less Clearing Costs (as each such term is defined in the Equity Line Agreement).

Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Maximum [Member] | Investor [Member]

Subsequent Event [Line Items]

Sale of stock, value

$ 5,000,000

Common stock, par value | $ / shares

$ 0.001